[go: up one dir, main page]

WO2025026968A1 - Mécanisme de dosage - Google Patents

Mécanisme de dosage Download PDF

Info

Publication number
WO2025026968A1
WO2025026968A1 PCT/EP2024/071438 EP2024071438W WO2025026968A1 WO 2025026968 A1 WO2025026968 A1 WO 2025026968A1 EP 2024071438 W EP2024071438 W EP 2024071438W WO 2025026968 A1 WO2025026968 A1 WO 2025026968A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosing mechanism
dose
friction brake
contact section
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/071438
Other languages
English (en)
Inventor
Timm KOEHLER
Paul Boosey
Joachim Keitel
Rahul MURKUTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medmix Switzerland AG
Original Assignee
Medmix Switzerland AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medmix Switzerland AG filed Critical Medmix Switzerland AG
Publication of WO2025026968A1 publication Critical patent/WO2025026968A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2403—Ampoule inserted into the ampoule holder
    • A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2485—Ampoule holder connected to rest of syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A61M2005/3151—Means for blocking or restricting the movement of the rod or piston by friction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31545—Setting modes for dosing
    • A61M5/31548—Mechanically operated dose setting member
    • A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
    • A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
    • A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button

Definitions

  • the present disclosure relates to dosing mechanisms for a medicament delivery device and to medicament delivery devices comprising the dosing mechanisms.
  • Dosing mechanisms for medicament delivery devices are configured to deliver at least one predetermined dose of medicament to a patient.
  • Such dosing mechanisms allow to first set the dose to be delivered in a dose setting state of the dosing mechanism and to then deliver a set dose in a dose delivery state of the dosing mechanism.
  • dosing mechanisms usually comprise a dose setting element that is actuated by a user to set the dose.
  • the dose setting element may be configured to be rotated by the user to set the dose.
  • the dosing mechanism thereby may be configured to allow only a single predetermined dose to be set or several varying predetermined doses.
  • dosing mechanisms usually comprise an actuation element, such as a push button, that is configured to be actuated by the user to deliver a set dose.
  • the dosing mechanisms usually comprise one or more members that are configured to move with respect to at least one other member during dose setting and that are restricted from moving with respect to the at least one other member during dose delivery or vice versa. This allows to transfer a force to a delivery member, such as a piston rod, only during dose delivery but not during dose setting.
  • a delivery member such as a piston rod
  • the dosing mechanism thereby comprises a piston rod and a threaded part that is threadedly engaged with the piston rod.
  • the threaded part is configured to rotate with respect to the piston rod and thereby to advance in an axial direction with respect to the piston rod to set a dose.
  • the threaded part is configured to remain rotationally stationary with respect to the piston rod. Axial movement of the threaded part then pushes the piston rod proximally to deliver a set dose.
  • a rotation of the threaded part is thereby prevented by a flexible detent member that engages with axial splines provided at a housing of the device. If, however, the flexible detent member is not strong enough to prevent rotation of the threaded part, the threaded part could rotate along the thread to the piston rod instead of pushing the piston rod via the locked thread. An amount of medicament delivered would then be lower than the dose previously set.
  • any relative movement of members during dose delivery that are configured to remain stationary with respect to each other during dose delivery may compromise dose accuracy.
  • any inhibition or restriction of relative movement of such members during dose setting might impede or prohibit setting of a dose.
  • medicament delivery devices usually comprise a medicament holder that contains the medicament to be delivered.
  • the medicament holder usually is releasably attached to a housing of the medicament delivery device to allow changing the medicament holder or a cartridge provided within the medicament holder after having delivered a last dose of medicament.
  • Such medicament delivery devices further usually comprise a cap that covers the medicament holder when the medicament delivery device is not in use. Detachment of the cap prior to using the medicament delivery device then may result in a loosening or even detachment of the medicament holder if the cap touches or engages the medicament holder, for example by a form fit or a frictional coupling.
  • medicament delivery devices having a housing and a cap attachable to the housing may require to attach the cap to the housing in a predetermined rotational orientation, for example to align visual indicators or other features provided at the cap and the housing. Since both the cap and the housing usually are configured as essentially cylindrical bodies, they in principle also allow to attach the cap to the housing in arbitrary rotational orientations.
  • the present disclosure provides a dosing mechanism for a medicament delivery device according to the independent claims. Embodiments are given in the dependent claims, the description, and the drawings.
  • the present disclosure is directed at a dosing mechanism for a medicament delivery device, the dosing mechanism comprising a first member, a second member and a friction brake.
  • the friction brake thereby is located in between a first contact section of the first member and a second contact section of the second member and the first member is configured to rotate with respect to the second member around a longitudinal axis during setting of a dose of medicament to be delivered.
  • the first member is configured to transfer an axial force to the second member in a proximal direction parallel to the longitudinal axis during dose delivery to deliver the dose.
  • the first contact section is configured to press the friction brake towards the second contact section during dose delivery so that the friction brake provides a rotation brake between the first member and the second member.
  • the dosing mechanism further comprises a hard stop that acts between the first member and the second member during dose delivery, wherein the hard stop is configured to restrict a movement of the first contact section towards the second contact section during dose delivery and to limit the pressure applied to the friction brake.
  • the hard stop thus prevents an uncontrolled compression of the friction brake and reliably defines the axial position of the first member with respect to the second member.
  • This increases dosing accuracy with respect to embodiments that do not feature such a hard stop and in which the hardness of the friction brake solely defines the relative axial positions of the first and second member.
  • variations of the hardness of the friction brake for example due to production tolerances and/or aging, do not compromise dosing accuracy.
  • the hard stop allows to limit the pressure applied to the friction brake to values that ensure that the friction brake reliably disengages after having completed dose delivery. This prevents the friction brake from inhibiting or impeding a subsequent dose setting operation.
  • the hard stop may be configured separate from the first and/or second contact section.
  • the hard stop may be axially and/or radially displaced with respect to the first and/or second contact section. This allows separating engagement of the hard stop from engagement of the friction brake.
  • the hard stop may restrict movement of the first contact section towards the second contact section by stopping relative movement between the first contact section and the second contact section. This may result in the contact sections initially moving towards each other at the beginning of a dose delivery operation and to then stop on engagement of the hard stop. Alternatively, the contact sections may already be prevented from moving relative to each other at the beginning of the dose delivery operation.
  • the first contact section may be configured as one of a contact surface, a contact edge, and a contact corner of a first contact structure.
  • the second contact section may be configured as one of a contact surface, a contact edge, and a contact corner of a second contact structure.
  • the first contact section may be integrally formed with the first member and/or the second contact section may be integrally formed with the second member.
  • the first contact section may be configured as a flat contact surface and/or the second contact section may be configured as a flat contact surface.
  • the dosing mechanism may comprise a piston rod that is configured to move into a medicament holder attachable to the dosing mechanism to deliver the dose from the medicament holder.
  • the axial force then may be transferred from the first member to the piston rod via the second member.
  • the dosing mechanism may be configured to non-releasably or releasably attach to the medicament holder.
  • the medicament holder may be configured as a container holder that receives a container, such as a cartridge, containing the medicament in its interior.
  • the medicament holder may comprise a compartment holding the medicament.
  • the piston rod may be rotationally fixed with respect to one of the first member and the second member at least during dose delivery.
  • the piston rod may be permanently rotationally fixed with respect to the one of the first member and the second member during both dose setting and dose delivery.
  • the one of the first member and the second member may, for example, be the first member.
  • the other one of the first member and the second member may be configured to rotate with respect to the piston rod during dose setting and may be configured to remain rotation- ally stationary with respect to the piston rod during dose delivery.
  • the other one of the first member and the second member may be coupled to the piston rod via a threaded connection.
  • the threaded connection may also be provided at one or more intermediate threaded parts that act between the piston rod and the other one of the first member and the second member.
  • the other one of the first member and the second member may be configured to rotate with respect to the piston rod during dose setting. Additionally or alternatively, it may be configured to remain rotationally stationary with respect to the piston rod during dose delivery.
  • the second member may be coupled to the piston rod via a threaded connection. It thereby may engage with the piston rod via the threaded connection.
  • Rotationally locking the first member to the second member during dose delivery may rotationally lock the threaded connection between the second member and the piston rod so that the second member is configured to transfer the axial force to the piston rod via the threaded connection.
  • the first member and the second member may be configured to remain axially stationary with respect to the piston rod during movement of the piston rod for delivering the set dose.
  • first member and/or the second member may be configured to move axially with respect to the piston rod during dose setting, for example upon changing a set dose.
  • first member and the second member may be configured to move axially with respect to the piston rod during dose setting and to remain axially stationary with respect to the piston rod during movement of the piston rod for delivering the set dose.
  • the piston rod thereby may move with respect to a housing of the dosing mechanism.
  • first member and the second member may be configured to remain rotationally stationary with respect to the piston rod during movement of the piston rod for delivering the set dose during dose delivery.
  • the dosing mechanism may comprise a housing and one of the first member and the second member, such as the first member, may be rotationally fixed with respect to the housing at least during dose setting.
  • the one of the first member and the second member may be permanently rotationally fixed with respect to the housing.
  • the piston rod may be rotationally fixed with respect to the housing of the dosing mechanism at least during dose delivery, such as during dose setting and dose delivery.
  • complete delivery of the set dose may require the first member and the second member to remain rotationally stationary with respect to each other during dose delivery and a rotation of the second member with respect to the first member during dose delivery may reduce a delivered dose below the set dose of medicament to be delivered.
  • the friction brake according to the present disclosure insures to reliably deliver the complete set dose and thus contributes to operational safety of the dosing mechanism.
  • the dosing mechanism may comprise a dose setting element that is configured to be gripped and actuated by a user to set the dose.
  • a dose setting element that is configured to be gripped and actuated by a user to set the dose.
  • one of the first member and the second member, such as the second member may be rotationally fixed to the dose setting element.
  • the dosing mechanism may comprise a dose setting element that is configured to be rotated by a user of the device to set the dose of medicament to be delivered.
  • the second member may be rotationally fixed to the dose setting element during dose setting.
  • the dose setting element may be configured to rotate with respect to the first member during dose setting.
  • the dose setting element may comprise a gripping structure that is configured to be gripped and rotated by a user of the dosing mechanism to set the dose of medicament to be delivered.
  • the dosing mechanism may comprise a first threaded connection that defines an axial position of the first member with respect to the housing and/or a second threaded connection that defines an axial position of the second member with respect to the piston rod.
  • the first threaded connection may act between a first threaded part and the housing and the second threaded connection may act between a second threaded part and the piston rod.
  • the first threaded part and the second threaded part may be rotationally fixed with respect to each other during dose setting. Furthermore, the first threaded part and the second threaded part may be rotationally movable with respect to each other during dose delivery.
  • the dosing mechanism may comprise a clutch that is configured to rotationally fix the first and second threaded part with each other during dose setting and to rotationally decouple the first threaded part from the second threaded part during dose delivery.
  • the dose setting element may be rotationally fixed with respect to both the first threaded part and the second threaded part.
  • the first threaded part may be configured as a dose member that is coupled between the first member and the housing.
  • the dose member may be axially movable or axially fixed with respect to the first member.
  • the first threaded part may be formed by the first member.
  • the first member then may be threadedly engaged with an intermediate member, such as a dose member, that acts between the first member and the housing.
  • the intermediate member may be axially fixed and rotationally movable with respect to the housing.
  • the second threaded part may be formed by the second member.
  • the second threaded part may be formed by an intermediate member that is rotationally fixed to the second member.
  • the intermediate member then may either be axially movable or axially fixed with respect to the second member.
  • the dosing mechanism comprises a threaded connection that defines an axial position of the first member with respect to a housing of the dosing mechanism.
  • the threaded connection may be, for example, the first threaded connection described above.
  • the first member may be configured to be driven in the axial direction via the threaded connection during dose delivery.
  • the threaded connection may act between the first member and the housing.
  • the dosing mechanism comprises a dose member that is coupled in between the first member and the housing, wherein the threaded connection acts between the dose member and the housing or between the dose member and the first member. If the threaded connection acts between the dose member and the housing, the threaded connection may define an axial position of the dose member with respect to the housing. If the threaded connection acts between the dose member and the first member, the threaded connection may define an axial position of the first member with respect to the dose member.
  • the dose member comprises a thread of the threaded connection.
  • the thread may be provided, for example, on an outer surface of the dose member. With other embodiments, the thread may also be provided on an inner surface of the dose member.
  • the dose member is configured to rotate with respect to the first member and the housing at least during dose delivery, such as during both dose setting and dose delivery.
  • the threaded connection acts between the dose member and the housing, wherein the dose member engages the housing via the threaded connection.
  • the threaded connection acts between the dose member and the first member, wherein the dose member engages the first member via the threaded connection.
  • the threaded connection acts between the dose member and the housing and a further threaded connection acts between the dose member and the first member. This allows for adapting the transmission ratio between the force exerted on the dose member and a resulting force at the first member by adapting the pitches of the threaded connection and the further threaded connection.
  • the dose member may engage the first member via the further threaded connection.
  • the dosing mechanism may comprise a dose definition mechanism that is configured to define a dose to be delivered with the dosing mechanism.
  • the dose definition mechanism thereby may define a rotational position of the second member with respect to the first member that corresponds to the dose.
  • the dose definition mechanism may be configured to define at least one dose. It thus may only define a single dose. Alternatively, it may be configured to define multiple doses.
  • the second member and/or the dose setting element may be configured to rotate with respect to the first member by at least one full revolution during dose setting. Alternatively, rotation of the second member and/or the dose setting element may be restricted to less than a full revolution during dose setting.
  • the axial force is transferred from the first member to the second member via the hard stop while the hard stop is restricting the movement.
  • the force exerted on the second member then does not depend on the hardness or elasticity of the friction member once the hard stop has limited relative movement between the first and second member.
  • the hard stop has a first stop part axially fixed to the first member and a second stop part axially fixed to the second member, wherein engagement of the first stop part with the second stop part during dose delivery restricts the movement of the first contact section with respect to the second contact section.
  • the first stop part thereby may be configured separate from the first contact section and/or the second stop part may be configured separate from the second contact section.
  • the first stop part may be configured as one of a surface, an edge, and a corner of a first stop element.
  • the second stop part may be configured as one of a surface, an edge, and a corner of a second stop element.
  • the first stop part is integrally formed with the first member and/or the second stop part is integrally formed with the second member. The first stop part then may be formed by the first member and the second stop part may be formed by the second member.
  • At least one of the first stop part and the second stop part circumferentially surrounds the longitudinal axis.
  • the at least one of the first stop part and the second stop part may form a ring-like structure surrounding the longitudinal axis.
  • the hard stop is configured as an axial stop. This provides a rigid construction of the hard stop that is adapted to reliably transfer axial forces.
  • the first stop part is configured to move against the second stop part parallel to the longitudinal axis upon engagement of the hard stop.
  • the hard stop has a first stop surface axially fixed to the first member and a second stop surface axially fixed to the second member, wherein the first stop surface and the second stop surface are orientated perpendicular to the longitudinal axis.
  • the first stop surface then may form the first stop part and the second stop surface may form the second stop part.
  • the first stop surface and/or the second stop surface such as both the first stop surface and the second stop surface, may have an angle with respect to the longitudinal axis, the angle being larger than zero.
  • the hard stop defines a maximal compression of the friction brake. This limits axial movement of the first member with respect to the second member upon engagement of the friction brake and allows for high dose accuracy.
  • the maximal compression is at most 0.2 mm, such as at most 0.15 mm, at most 0.1 mm, at most 0.09 mm, at most 0.08 mm or at most 0.07 mm.
  • the maximal compression may be at most 20%, such as at most 15%, at most 10%, at most 9%, at most 8% or at most 7% of a height of the friction brake, such as a height of the friction brake along a longitudinal axis of the dosing mechanism.
  • the first contact section circumferentially extends around the longitudinal axis and/or the second contact section circumferentially extends around the longitudinal axis. This equally and symmetrically distributes a pressure applied by the axial force to the friction brake.
  • the first contact section is configured as a surface that is perpendicular to the longitudinal axis and/or the second contact section is configured as a surface that is perpendicular to the longitudinal axis. Such a configuration facilitates disengagement of the first and second contact section upon axially moving the first member away from the second member.
  • the first contact section is configured as a first surface and the second contact section is configured as a second surface, wherein the first surface is parallel to the second surface.
  • the friction brake is configured to act as a friction-based clutch in between the first member and the second member to prevent rotation of the first member with respect to the second member.
  • the first contact section pressing the friction brake towards the second contact section during dose delivery establishes a friction fit that rotationally locks the first member to the second member.
  • the friction fit may additionally lock the second member to the housing.
  • the friction brake is configured to be axially compressed in between the first contact structure and the second contact structure.
  • the hard stop defines a gap between the first contact section and the second contact section during dose delivery, wherein the gap accommodates the friction brake, wherein, for example, the gap is an axial gap.
  • the friction brake is configured as a separate friction member that is placed in between the first contact section and the second contact section. This allows the friction brake to have a different material than the first contact section and/or the second contact section. Furthermore, it allows the friction brake to have a different shape than the first contact section and/or the second contact section. As a consequence, elastic and/or frictional parameters of the friction brake may be adapted over a wide range.
  • the friction brake is configured as a ring-like structure, such as a torus or a washer.
  • the friction brake may be configured as an O-ring.
  • Such parts are easily available as ready-made parts and allow for simple and cost-effective manufacture of the dosing mechanism.
  • the hard stop defines a gap between the first contact section and the second contact section during dose delivery, wherein the gap accommodates the friction brake.
  • a width of the gap then may define the compression of the friction brake.
  • the gap is an axial gap.
  • the gap then may separate the first and second contact section along the longitudinal axis.
  • the first member does not axially overlap with the friction brake in between the friction brake and the second contact section of the second member.
  • the second member may not axially overlap with the friction brake in between the friction brake and the first contact section of the first member. Consequently, the entire cross section of the friction brake perpendicular to the longitudinal axis may be exposed to the first contact section and/or the second contact section.
  • a lack of an axially overlap may reduce the probability that the first contact section interferes with the second member upon the first contact section engaging with the friction brake.
  • a probability that the second contact section interferes with the first member upon the second contact section engaging with the friction brake also may be reduced.
  • the first member does not axially overlap with the friction brake in directions parallel to the longitudinal axis within a half space bounded by a plane through the center of the friction brake.
  • the plane through the center of the friction brake is orientated perpendicular to the longitudinal axis.
  • the half space is located at a side of the plane that faces away from the first contact section.
  • the second member does not axially overlap with the friction brake in directions parallel to the longitudinal axis within a further half space bounded by the plane through the center of the friction brake.
  • the plane through the center of the friction brake is orientated perpendicular to the longitudinal axis.
  • the further half space is located at a side of the plane that faces away from the second contact section.
  • one of the first member and the second member forms a support member, wherein the friction brake is located on an outer surface of the support member.
  • the second member may form the support member.
  • the support member may have a cylindrical portion or body and the friction brake may be located at the cylindrical portion or body.
  • the friction brake may comprise an opening to receive the cylindrical portion or body.
  • the friction brake is axially retained on the support member, for example by a friction fit.
  • the friction brake may comprise an elastic material and the friction brake may be mounted to the support member in a stretched state. This further retains the friction brake on the support member.
  • the first contact section may be provided at a cylindrical portion or body of the first member.
  • the first contact section may be provided at a cylindrical surface, such as an outer or inner surface, of the first member.
  • the first contact section may be provided at a contact structure that protrudes from the cylindrical surface.
  • the first contact structure may radially protrude from the cylindrical surface of the first member in a radial direction perpendicular to the longitudinal axis.
  • the first contact section being provided at a cylindrical surface of the first member is not an essential feature the present disclosure.
  • the first member may generally comprise a first contact structure, wherein the first contact structure comprises the first contact section.
  • the first contact structure may be configured as a radial protrusion that protrudes from a surface of the first member in a radial direction perpendicular to the longitudinal axis, for example from a cylindrical surface of the first member.
  • the first contact structure may form a ring-like structure that fully extends circumferentially around the longitudinal axis.
  • the first contact section may be provided at a radial flange.
  • the radial flange may form the first contact structure.
  • the second contact section may be provided at a cylindrical portion or body of the second member.
  • the second contact section may be provided at a cylindrical surface, such as an outer or inner surface, of the second member.
  • the second contact section may be provided at a contact structure that protrudes from the cylindrical surface.
  • the second contact structure may radially protrude from the cylindrical surface of the second member in a radial direction perpendicular to the longitudinal axis.
  • the second contact section being provided at a cylindrical surface of the second member is not an essential feature the present disclosure.
  • the second member may generally comprise a second contact structure, wherein the second contact structure comprises the second contact section.
  • the second contact structure may be configured as a radial protrusion that protrudes from a surface of the second member in a radial direction perpendicular to the longitudinal axis, for example from a cylindrical surface of the second member.
  • the second contact structure may form a ring-like structure that fully extends circumferentially around the longitudinal axis.
  • the second contact section may be provided at a radial flange.
  • the radial flange may form the second contact structure.
  • At least one of the first member and the second member comprises an axially protruding part extending from the one of the first member and the second member parallel to the longitudinal axis, wherein the hard stop is formed between the axially protruding part and the other one of the first member and the second member, such as the second member.
  • the hard stop may be formed by engagement of the axially protruding part with the other one of the first member and the second member.
  • the axially protruding part at least partially surrounds the friction brake in a radial direction perpendicular to the longitudinal axis.
  • the axially protruding part axially extends from the contact section of the one of the first member and the second member parallel to the longitudinal axis.
  • one of the first member and the second member forms an inner member and the other one of the first member and the second member forms an outer member, wherein the outer member at least partly, such as completely, surrounds the inner member.
  • the outer member may at least partly, such as completely, surround the contact section of the inner member.
  • the outer member may be formed by the first member and the inner member may be formed by the second member.
  • the outer member radially overlaps with the friction brake, wherein, for example, the friction brake is located in an end cavity of the outer member.
  • the end cavity may be located at an axial end of the outer member.
  • the end cavity may be located at a proximal end of the outer member.
  • the end cavity may be open at the axial end.
  • the end cavity may form a cylindrical cavity at an end of the outer member.
  • the outer member may at least partly surround the friction brake in the radial direction perpendicular to the longitudinal axis.
  • the friction brake may be mounted to the inner member.
  • the friction brake then may contact a surface of the inner member, such as an outer surface of the inner member.
  • the outer member is radially spaced from the friction brake by a clearance. This prevents the outer member from touching and moving the friction brake when shifting with respect to the inner member, for example along the longitudinal axis.
  • the outer member may be radially spaced from the friction brake by the clearance in the radial direction perpendicular to the longitudinal axis, such as in all radial directions perpendicular to the longitudinal axis.
  • the radial directions thereby may be orientated from a center of the friction brake radially outwards perpendicular to the longitudinal axis.
  • the center may be centered with respect to the friction brake parallel to the longitudinal axis.
  • the outer member may additionally be configured to touch the friction brake with its respective contact section while maintaining the clearance in the radial direction.
  • the clearance is smaller than the radial height of the friction brake. This may prevent the friction brake from snapping over a contact structure that axially retains the friction brake on the inner member by limiting radial movement of the friction brake at the outer member.
  • the clearance is at most 0.5 times, such as at most 0.4 times, or at most 0.3 times a radial height of the friction brake.
  • the inner member forms the support member.
  • the friction brake then is mounted on the inner member and at least partly, such as completely, surrounded by the outer member.
  • the first contact section axially overlaps with the friction brake over a first radial height that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height of the friction brake.
  • the second contact section may axially overlap with the friction brake over a second radial height that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height of the friction brake.
  • the radial height of the friction brake may be the radial thickness of the ring that is the difference between an outer diameter and an inner diameter of the friction brake.
  • the first contact structure comprising the first contact section axially overlaps with the friction brake over a first radial height that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height of the friction brake.
  • the second contact structure comprising the second contact section may axially overlap with the friction brake over a second radial height that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height of the friction brake.
  • a large overlap of the individual contact sections and/or contact structures with the friction brake in the radial direction helps to prevent the friction brake from axially shifting along the longitudinal axis.
  • the friction brake is located in a cavity formed between the first member and the second member, wherein the cavity is radially bounded by the first member and the second member in radial directions perpendicular to the longitudinal axis and axially bounded in directions parallel to the longitudinal axis by a first contact structure comprising the first contact section and a second contact structure comprising the second contact section. Furthermore, a first radial spacing between the first contact structure and the second member is smaller than the radial height of the friction brake and/or a second radial spacing between the second contact structure and the first member is smaller than the radial height of the friction brake. This securely fixes the friction brake in between the first and second member.
  • the friction brake is configured as an elastic member, wherein, for example, the friction brake comprises rubber or consists of rubber.
  • the rubber may be a natural rubber or it may be a synthetic rubber.
  • the rubber may be nitrile butadiene rubber (NBR).
  • a hardness of the friction brake is lower than a hardness of the first contact section and/or a hardness of the second contact section. This provides a well-defined compression of the friction brake in between the first and second contact sections that is primarily given by the hardness of the friction brake.
  • the friction brake has at most a Shore A hardness of 90, such as at most a Shore A hardness of 85, at most a Shore A hardness of 80, or at most a Shore A hardness of 75. These values have proven to be suited for typical dosing mechanisms.
  • the dosing mechanism comprises a further stop, wherein the further stop acts between the first member and the second member and wherein the further stop restrains axial movement of the first contact section away from the second contact section during dose setting.
  • the further stop may be configured as an axial stop. It may comprise a first further stop part and a second further stop part that engage with each other to restrict axial movement of the first contact section away from the second contact section.
  • the first further stop part may be integrally formed with the first member and/or the second further stop part may be integrally formed with the second member.
  • one of the first member and the second member is permanently rotationally fixed to the housing of the dosing mechanism.
  • the one of the first member and the second member may, for example, be axially movable with respect to the housing. It may, for example, be connected to the housing via a splined connection.
  • the one of the first member and the second member may be rotationally fixed to the housing during both dose setting and dose delivery.
  • the dosing mechanism comprises a latching mechanism that defines discrete rotational positions of the second member with respect to the first member.
  • the first member thereby is permanently rotationally fixed to a first latching part of the latching mechanism and the second member is permanently rotationally fixed to a second latching part of the latching mechanism.
  • the first latching part and the second latching part releasably engage with each other upon relative rotation of the first member relative to the second member during dose setting and the latching mechanism provides an additional rotation brake preventing relative rotation of the first member and the second member during dose delivery.
  • the latching mechanism may provide the dose definition mechanism that defines at least one rotational position of the first member with respect to the second member that corresponds to at least one settable dose.
  • the second latching part is axially fixed to the second member and the second contact section and the second latching part are separate from each other. This prevents the first contact section from interfering with the second latching part via the friction brake.
  • the second contact section may be axially displaced with respect to the second latching part.
  • a gap may be formed between the second latching part and the second contact section.
  • Both the second contact section or the second contact structure comprising the second contact section and the second latching part may protrude radially from the second member.
  • the dosing mechanism may comprise a dose definition mechanism that allows a user of the device to set at least one dose of medicament for delivery.
  • the dose definition mechanism may be configured to allow only a single predetermined dose to be set.
  • the dose definition mechanism may also be configured to allow a multitude of differing doses to be set by the user, such as two or more differing doses.
  • the dose definition mechanism may allow to set multiple doses that differ by equidistant dose steps.
  • the dosing mechanism may be configured as a single-use mechanism that allows to set a dose only once and subsequently prevents a user from setting and delivering further doses.
  • the dosing mechanism may also be configured as a multi-use mechanism that allows to repeatedly set doses for delivery.
  • the dosing mechanism may be configured as a disposable mechanism that is disposed of after having delivered a last dose from a medicament container attached to the dosing mechanism. With other embodiments, the dosing mechanism may be configured as a reusable mechanism that is configured to detach from the medicament holder after having delivered a last dose from the medicament holder and to attach to a medicament holder comprising at least one additional dose to be delivered by the dosing mechanism.
  • a delivery of the medicament may require an axial force to be exerted by a user, for example on an actuation member of the dosing mechanism.
  • the user may have to exert the axial force with respect to the housing.
  • the dosing mechanism may be configured as an automatic mechanism that is configured to deliver the dose of medicament without requiring a transfer of a force provided by the user to a member that is in contact with the medicament and moves for delivering the medicament, such as to a piston sealing a compartment comprising the medicament.
  • the axial force for delivering the dose may be provided by an energy storage, such as a spring.
  • the structural details and technical effects of the friction brake and the hard stop are completely independent from the structural components that provide the axial force that is transferred from the first member to the second member to deliver the dose.
  • the force may be directly imparted onto the first member from an energy storage or by a user of the device.
  • the force may be imparted onto the first member via one or more intermediate members.
  • One of the intermediate members may, for example, be the dose member described above.
  • the dosing mechanism comprises a button that is operatively coupled to the first member during dose delivery so that axial movement of the button causes axial movement of the first member during dose delivery.
  • a button may form the actuation member. Pushing the button during dose delivery may generate the axial force that is transferred from the first member to the second member during dose delivery.
  • the button may be coupled to the first member via a gear that is configured to convert the axial movement of the button into axial movement of the first member.
  • the gear may have a transmission ratio different from one.
  • a speed of the axial movement of the button may differ from a speed of the axial movement of the first member.
  • the speed of the axial movement of the button may be larger than the speed of the axial movement of the first member.
  • the axial force transferred from the first member to the second member then would be larger than the axial force imparted on the button.
  • the present disclosure is directed at a dosing mechanism for a medicament delivery device, the dosing mechanism comprising a first member, a second member and a friction brake.
  • the friction brake thereby is located in between a first contact section of the first member and a second contact section of the second member and the first member is configured to rotate with respect to the second member around a longitudinal axis during setting of a dose of medicament to be delivered.
  • the first member is configured to transfer an axial force to the second member in a proximal direction parallel to the longitudinal axis during dose delivery to deliver the dose.
  • the first contact section is configured to press the friction brake towards the second contact section during dose delivery so that the friction brake provides a rotation brake between the first member and the second member.
  • the dosing mechanism then may not comprise the hard stop.
  • the present disclosure is directed at a medicament delivery device having one of the dosing mechanisms according to the present disclosure.
  • the medicament delivery device may be configured as an injection device, such as a pen injection device.
  • a medicament holder containing the medicament to be delivered may be configured to receive or hold a cannula at its proximal end to deliver the medicament through the cannula.
  • the present disclosure also is directed at a medicament delivery device having a medicament holder, a housing, and a cap, wherein the medicament holder is configured to releasably attach to the housing via a connector by rotating the medicament holder around a longitudinal axis with respect to the housing and wherein the cap is configured to releasably attach to the medicament holder to at least partly cover the medicament holder.
  • the medicament delivery device may have one of the dosing mechanisms according to the present disclosure.
  • the medicament delivery device may also have dosing mechanisms that are different from the dosing mechanisms according to the present disclosure.
  • the medicament holder comprises a first blocking element of a blocking mechanism that is configured to engage with a second blocking element of the blocking mechanism, the second blocking element being provided at the housing.
  • the blocking mechanism thereby is configured to be interlocked by the cap to rotationally lock the medicament holder to the housing when the cap is attached to the medicament holder and the blocking mechanism is configured to be unlocked to allow rotation of the medicament holder with respect to the housing when the cap is detached from the medicament holder. Detachment of the cap from the housing thereby may release the interlock that rotationally locks the medicament holder to the housing.
  • Such first and second blocking elements prevent rotation of the medicament holder upon detachment of the cap from the medicament holder.
  • one of the first blocking element and the second blocking element is attached to a flexible element that is configured to bend away from the other one of the first blocking element and the second blocking element to allow the rotation of the medicament holder with respect to the housing. Furthermore, attachment of the cap to the medicament holder blocks the flexible element from bending.
  • the first blocking element may be attached to the flexible element.
  • the cap is configured to engage with the flexible element to block the flexible element from bending.
  • the flexible element is configured to bend radially outwards to allow the rotation of the medicament holder with respect to the housing.
  • the medicament holder then may be configured to move the flexible element into the cap to interlock the blocking mechanism.
  • the flexible element is provided at the medicament holder.
  • the flexible element is integrally formed with the medicament holder.
  • the flexible element may be formed within an outer wall of the medicament holder.
  • the flexible element may be configured as a free-standing structure that is surrounded by a gap formed in the medicament holder, such as in the outer wall of the medicament holder.
  • the flexible element is accessible at an outer surface of the medicament holder.
  • the outer surface may form an outer surface of the outer wall of the medicament holder.
  • the flexible element has a fixed first end and a free second end, wherein the one of the first and second blocking element is attached to the second end and wherein the first end is located opposite the second end along the longitudinal axis.
  • the flexible element being orientated axially provides equal resistance to the one of the first and second blocking element irrespective of a rotation direction of the first blocking element with respect to the second blocking element.
  • the blocking mechanism is configured as a radial block, wherein the first blocking element is configured to engage with the second blocking element by rotating with respect to the second blocking element around the longitudinal axis.
  • one of the first blocking element and the second blocking element is configured as a radial protrusion and the other one of the first blocking element and the second blocking element is configured as a radial detent that is configured to receive the radial protrusion.
  • the first blocking element of the medicament holder may be configured as the radial protrusion and the second blocking element of the housing may be configured as the radial detent.
  • the radial detent has a larger length in a circumferential direction than the radial protrusion. This allows the blocking mechanism to rotationally lock the medicament holder to the housing over a range of relative rotational positions of the medicament holder with respect to the housing.
  • the range thereby may include all rotational positions that the medicament holder takes up during the lifetime of the medicament delivery device. Those rotational positions may, for example, be given by a maximum wear of the connector for attaching the medicament holder to the housing.
  • the radial detent has a first side surface in a first circumferential direction and a second side surface in a second circumferential direction opposite the first circumferential direction, wherein the first side surface is engaged by the radial protrusion upon rotating the medicament holder to detach the medicament holder from the housing.
  • the first side surface thereby is steeper than the second side surface.
  • the first blocking element may be located in a protruding axial section, in which an outer surface of the medicament holder has a larger radial extent than in an adjacent recessed axial section.
  • the first blocking element then may be configured to disengage from the inner surface of the cap only when the inner surface of the cap leaves the protruding axial section. This prevents the inner surface of the cap from interfering with the medicament holder after having unlocked the blocking mechanism.
  • the recessed section may extend from the protruding axial section up to a proximal end of the medicament holder.
  • the connector comprises a first connection element provided at the medicament holder, wherein the first connection element is configured as a female connector that is configured to receive a second connection element provided at the housing.
  • the second connection element then may be configured as a male connector.
  • the first connection element may be configured as an inner thread and the second connection element may be configured as an outer thread.
  • the connector is configured as a threaded connector.
  • the connector may, for example, be configured as a bayonet lock.
  • the medicament holder comprises a first cap lock element that is configured to engage with a second cap lock element of the cap to axially hold the cap at the medicament holder.
  • the first cap lock element and the second cap lock element may be configured as a snap fit connection.
  • a cap lock formed by the first cap lock element and the second cap lock element is configured as an axial lock that does not restrict rotation of the cap with respect to the medicament holder.
  • the medicament holder comprises a first aligning part of a cap alignment mechanism and the cap comprises a second aligning part of the cap alignment mechanism, wherein the first aligning part is configured to engage with the second aligning part upon attachment of the cap to the medicament holder to attach the cap in a predefined rotational orientation to the housing.
  • the cap alignment mechanism may be configured to prevent rotation of the cap with respect to the housing at least when the cap is fully attached to the housing.
  • the cap alignment mechanism may be configured to prevent rotation of the cap by the first aligning part engaging with the second aligning part when the cap is fully attached to the housing.
  • the first aligning part and/or the second aligning part comprise a lead-in taper that narrows in a distal direction parallel to a longitudinal axis.
  • both the first aligning part and the second aligning part comprise the lead-in taper, wherein a first taper angle of the first aligning part is larger than a second taper angle of the second aligning part.
  • the lead-in taper is configured as a non-self-locking taper, wherein the lead-in taper forces the cap to move in a proximal direction parallel to the longitudinal axis upon rotating the cap while being fully attached to the housing. This allows a user to detach the cap by rotating it with respect to the housing and thus provides a rotate-to-unlock mechanism.
  • one of the first aligning part and the second aligning part is configured as a radial protrusion and the other one of the first aligning part and the second aligning part is configured as a radial depression that receives the radial protrusion upon attachment of the cap to the housing.
  • the radial depression has an open proximal end.
  • the open proximal end may be configured to receive the radial protrusion upon axially moving the cap onto the medicament holder.
  • the radial depression comprises a first radial sidewall and the radial protrusion comprises a second radial sidewall, wherein the first radial sidewall and/or the second radial sidewall are angled with respect to a radial plane perpendicular to the longitudinal axis and wherein the first radial sidewall is configured to slide along the second radial sidewall upon attachment of the cap to the housing to align the cap in the predefined rotational orientation.
  • the first radial sidewall and/or the second radial sidewall are angled with respect to the longitudinal axis. This may provide the lead-in taper.
  • the first radial sidewall and the second radial sidewall comprise an undercut in a cross-sectional plane perpendicular to the longitudinal axis. Such undercuts prevent disengagement of first and second aligning parts.
  • the cap comprises a first member comprising the second aligning part and a second member non-releasably joined to the first member, for example by an adhesive bond.
  • the first member thereby may be glued to the second member.
  • the first member may be configured as a cap end element and the second member may be configured as a cap body.
  • the first member comprises a further first aligning part of a body alignment mechanism and the second member comprises a further second aligning part of the body alignment mechanism, wherein the engagement of the further first aligning part with the further second aligning part is configured to rotationally align the first member with respect to the second member.
  • the further first aligning part may be configured as a radial protrusion and the further second aligning part may be configured as a radial recess, such as a radial notch, that receives the radial protrusion.
  • the first member forms an inner part and the second member forms an outer part at least partly surrounding the inner part.
  • the first member comprises a plastic material, for example consists of the plastic material
  • the second member comprises a metal material, for example consists of the metal material
  • the cap comprises a cap body and a cap end element, wherein the cap end element is located at a proximal end of the cap body and wherein the second aligning part is formed at the cap end element.
  • the first aligning part is made from a plastic material, such as a thermoplastic material.
  • the second aligning part may be made from a plastic material, such as a thermoplastic material. This provides for cost efficient and easy manufacture of the first and/or second aligning part.
  • the first aligning part is configured as a molded part, such as an injection molded part.
  • the second aligning part may be configured as a molded part, such as an injection molded part.
  • the first aligning part and the second aligning port may be configured to only engage when the cap has been moved over the medicament holder by at least 0.5 times, such as at least 0.6 times or at least 0.7 times the total length of the medicament holder covered by the cap in a fully attached state.
  • the first aligning part is located at a proximal end of the medicament holder and/or the second aligning part is located at a proximal end of the cap.
  • the first aligning part may be located in a proximal half, such as a proximal quarter of the medicament holder and/or the second aligning part may be located in a proximal half, such as a proximal quarter of the cap.
  • a rotation lock is provided between the medicament holder and the cap that rotationally locks the cap to the medicament holder when the cap is fully attached to the medicament holder.
  • the rotation lock is provided by engagement of the cap with the medicament holder, such as by engagement of a cap end element of the cap with the medicament holder.
  • the rotation lock comprises a locking member of the medicament holder and a locking member of the cap, whereby the locking member of the medicament holder and the locking member of the cap are configured to engage with each other to prevent rotation of the cap with respect to the medicament holder.
  • the locking member of the medicament holder and/or the locking member of the cap extend in a length direction parallel to the longitudinal axis.
  • the locking member of the medicament holder is provided at an outer surface of the medicament holder and the locking member of the cap is provided at an inner surface of the cap.
  • one of the locking member of the medicament holder and the locking member of the cap is formed by a longitudinal recess and the other one of the locking member of the medicament holder and the locking member of the cap, for example the locking member of the cap, is configured as a longitudinal protrusion that is configured to be received in the longitudinal recess to prevent rotation of the cap with respect to the medicament holder.
  • the recess is open at least at its proximal end, wherein, for example, the recess is open at both its proximal end and at its distal end.
  • the rotation lock comprises at least one sidewall, such as two opposing sidewalls, of the medicament holder engaging with at least one sidewall, such as with two opposing sidewalls, of the cap.
  • the present disclosure is also directed at a medicament holder having the features of the medicament holder of the medicament delivery device according to the present disclosure. Furthermore, the present disclosure relates to a housing having the features of the housing of the medicament delivery device according to the present disclosure.
  • the devices and mechanisms according to the present disclosure may be configured to dispense a drug or, used synonymously herein, a medicament.
  • a drug or a medicament is a pharmaceutical formulation that contains one or more active pharmaceutical ingredients.
  • An active pharmaceutical ingredient is a substance that is biologically active or has a biological effect on humans or animals. It is used in the diagnosis, mitigation, cure, treatment or prevention of a medical condition or to otherwise affect the structure or function of the body of humans or animals.
  • Active pharmaceutical ingredients, medicaments and drugs that may be contained and/or dispensed by the mechanisms and devices according to the present disclosure are, inter alia, described in handbooks such as Merck Index, for example 15 th edition, Rote Liste, such as Rote Liste 2023, the publication Approved Drug Products with Therapeutic Equivalence Evaluations ⁇ Orange Book) by the U.S. FDA and the Purple Book Database of Licensed Biological Products, also by the U.S. FDA, all of which are freely accessible via the Internet.
  • Active pharmaceutical ingredients, medicaments and drugs that may be contained and/or dispensed by the mechanisms and devices according to the present disclosure may be selected from: analgesics and antirheumatics (main group 05 of Rote Liste); anti-obesity drugs (main group 06 of Rote Liste); antialler- gics (main groups 07 of Rote Liste); antianemics (main group 08 of Rote Liste); antibiotics (main group 10 of Rote Liste); antidiabetic drugs (main group 12 of Rote Liste); antidote medications (main group 13 of Rote Liste); antihemorrhagics (antifibrinolytics and other hemostatic agents) (main group 16 of Rote Liste); antihypoglycemic drugs (main group 18 of Rote Liste); antihypotonics and agents for shock therapy (main group 19 of Rote Liste); anticoagulants (main group 20 of Rote Liste); beta-receptor blockers, calcium channel blockers and inhibitors of the renin-angiotensin-aldo
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an antirheumatic.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an anti-obesity drug.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an antiallergic.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an antibiotic.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an antidiabetic drug.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an antihypoglycemic drug.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an enzyme inhibitor.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a preparation for enzyme deficiency.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a transport protein.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a gene therapeutic.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a cell therapeutic.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an RNA interference therapeutics.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a hypophysial hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a hypothalamic hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a regulatory peptide other than a hypophysial hormone or a hypothalamic hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an inhibitor of a hypophysial hormone. In a further specific example, an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an inhibitor of a hypothalamic hormone. In a further specific example, an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an inhibitor of a regulatory peptide other than a hypophysial hormone or a hypothalamic hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an analogue of a hypophysial hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an analogue of a hypothalamic hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an analogue of a regulatory peptide other than a hypophysial hormone or a hypothalamic hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an immunomodulator.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a lipid-lowering drug.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an osteoporosis agent.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a calcium metabolism regulator.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a bone metabolism regulator.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a sex hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an inhibitor of a sex hormone.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is an autoimmune disorder medication.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a rheumatoid arthritis medication.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a multiple sclerosis medication.
  • an active ingredient of a medicament delivered by the mechanisms and devices according to the present disclosure is a cardiovascular disease medication.
  • the drug or medicament may have, for example, one or more active pharmaceutical ingredients selected from one or more of: carbohydrates and polysaccharides; polypeptides, peptides and proteins (e.g., antibodies, antibody fragments, hormones, growth factors, and enzymes); small molecules with a molecular weight of 500 Da or less; and nucleic acids, double or single stranded DNA (including cDNA and naked DNA), RNA, antisense nucleic acids, such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be included into molecular delivery systems such as liposomes, vectors, or plasmids.
  • active pharmaceutical ingredients selected from one or more of: carbohydrates and polysaccharides; polypeptides, peptides and proteins (e.g., antibodies, antibody fragments, hormones, growth factors, and enzymes); small molecules with a molecular weight of 500 Da or less; and nucleic
  • the drugs or medicaments contained in or dispensed with the mechanisms according to the present disclosure may comprise active pharmaceutical ingredients used in the treatment and/or mitigation and/or prevention and/or cure and/or diagnosis of many different types of medical conditions. These may include, inter alia, one or more of the following conditions: acute coronary syndrome, angina, myocardial infarction, anaphylactic shock, atherosclerosis, diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus such as diabetic retinopathy, cancer, macular degeneration, inflammation, hay fever, rheumatoid arthritis, thromboembolism disorders such as deep vein or pulmonary thromboembolism, infertility, growth disorder, migraine, autoimmune disorders, multiple sclerosis, osteoporosis, allergies, obesity, and/or cardiovascular diseases.
  • acute coronary syndrome angina, myocardial infarction, anaphylactic shock, atherosclerosis, diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus such as diabetic
  • the condition may be diabetes mellitus.
  • the condition may be a complication associated with type 1 diabetes mellitus.
  • the condition may be a complication associated with type 2 diabetes mellitus.
  • the condition may be diabetic retinopathy.
  • the condition may be an inflammation.
  • the condition may be rheumatoid arthritis.
  • condition may be infertility.
  • the condition may be growth disorder.
  • condition may be migraine.
  • the condition may be an autoimmune disorder.
  • the condition may be multiple sclerosis.
  • the condition may be osteoporosis.
  • the condition may be an allergy.
  • the condition may be obesity.
  • the condition may be a cardiovascular disease.
  • the active pharmaceutical ingredients for the therapy of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, such as, human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1 ), GLP-1 analogues or GLP- 1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof.
  • an insulin such as, human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1 ), GLP-1 analogues or GLP- 1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof.
  • the active pharmaceutical ingredient may also be a hormone, such as a hypophysis hormone or a hypothalamus hormone or a regulatory active peptide and an antagonist of a regulatory active peptide.
  • the hormone may be a fertility hormone, a gonadotropine, a growth hormone, a steroid hormone, such as testosterone or oestrogen, a parathyroid hormone, such as teriparatide, epinephrine or a follicle-stimulating hormone.
  • the active pharmaceutical ingredient may also be an oligonucleotide.
  • the active pharmaceutical ingredient may also be an antibody.
  • antibody includes an immunoglobulin molecule or an antigen-binding portion, such as a fragment antigen-binding region, of an immunoglobulin molecule, an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins, and/or a dual variable region antibody-like binding protein having cross-over binding region orientation (CODV).
  • the antibody may be a monoclonal, a polyclonal, a recombinant, or a chimeric antibody. It may be a de-immunized or humanized, a fully human, or a non-human, such as a murine, antibody.
  • the antibody may be a single chain antibody.
  • the active pharmaceutical ingredient may also be a polysaccharide, such as a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof.
  • the active pharmaceutical ingredient may also be a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • the drug or medicament contained in and/or dispensed with the mechanisms and devices according to the present disclosure may include one or more of the following active pharmaceutical ingredients: abatacept, adalimumab, aflibercept, alirocumab, anakinra, apomorphine, aripiprazole, belimumab, benral- izumab, betamethasone, bimekizumab, brodalumab, brolucizumab, buprenorphine, certolizumab pegol, choriogonadotropin alfa, cyanocobalamin, carbepoetin alfa, denosumab, dulaglutide, dupilumab, enoxap- arin sodium, epinephrine, epoetin, epoetin alfa, epoetin beta, epoetin theta, epoetin zeta,
  • the drug or medicament contained in and/or dispensed with the mechanisms and devices according to the present disclosure may include one or more of the following active ingredients: Lixisenatide, Taspoglutide, Albiglutide, Efpeglenatide, GLP-1 Eligen, Nodexen, Pegapamod- tide, Tirzepatide, and Bamadutide.
  • the drug or medicament dispensed with the mechanisms and devices according to the present disclosure may include one or more of the following active ingredients: Mipomersen sodium, Linagliptin, Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine, Lutropin, Choriongonadotropin, Desmopressin, Terlipressin, Gonadorelin, Buserelin, Nafarelin, Hylan G-F 20.
  • the drug or medicament dispensed with the mechanisms and devices according to the present disclosure may include as an active ingredient a piperidine alkaloid, such as azimine, azithromycine, azcarpine, and/or carpaine.
  • a piperidine alkaloid such as azimine, azithromycine, azcarpine, and/or carpaine.
  • the drug or medicament may also contain one or more of the following: pharmaceutically acceptable solvents or salts of the active pharmaceutical ingredients described herein; analogues and derivates of the active pharmaceutical ingredients described herein; biosimilars of the active pharmaceutical ingredients described herein; and pharmaceutically acceptable carriers of the active pharmaceutical ingredients described herein.
  • the drug or medicament contained in and/or dispensed with the mechanisms and devices according to the present disclosure may include one or more of the following active pharmaceutical ingredients: paracetamol (acetaminophen), nonsteroidal anti-inflammatory drugs, such as aspirin, ibuprofen and naproxen, cox-2 inhibitors, such as rofecoxib, celecoxib, and etoricoxib, opioids, such as morphine, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, alcohols, cannabis, nefopam, flupirtine, ziconotide.
  • paracetamol acetaminophen
  • nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen and naproxen
  • cox-2 inhibitors such as rofecoxib, celecoxib, and etoricoxib
  • opioids such as morphine, codeine, oxycodone, hydrocodone, dihydromorphine, pe
  • the drug or medicament may be contained in a container from which it is dispensed by an action of a user.
  • the container may, for example, be a cartridge, a reservoir or a syringe.
  • the container may extend between a dispensing end and a rear end of the container.
  • the container may be configured to dispense the drug or medicament at the dispensing end, for example through a pierceable septum.
  • the container may be sealed to prevent the exit of the drug or medicament.
  • the container may be sealed by a flexible and/or displaceable plunger at the rear end.
  • the container In between the dispensing end and the rear end, the container may have a generally tubular hollow housing.
  • the container may have a single compartment for storing the drug or medicament.
  • the container may also have more than one compartment, such as two compartments.
  • Different compartments thereby may comprise different substances, such as drugs, medicaments, active ingredients, solvents or carriers.
  • Different compartments may also comprise a part of the medicament or drug in solid form, for example as a powder, such as a lyophilized powder, and another part of the medicament in liquid form.
  • the solid part may, for example, comprise the one or more active pharmaceutical ingredient and/or the liquid part may be a solvent.
  • the container may be configured to allow a mixing of the contents from at least two of the compartments, such as from all of the compartments, prior to and/or during dispensing of the medicament or drug.
  • the container may be configured to provide a fluid connection between the at least two, such as between all of the compartments, for mixing.
  • the container may comprise two compartments, one comprising a first part of the drug or medicament in solid form, for example the one or more active ingredients, and the other one comprising a second part of the drug or medicament in liquid form, such as a solvent.
  • the container may be configured to provide a fluid connection between the two compartments and to mix the first and second parts prior or during dispensing. This may reconstitute the drug or medicament from its solid form.
  • Some devices and mechanisms according to the present disclosure may be disposable, which means that the container holding the medicament is non-replaceable or non-refil lable and the devices are disposed of after having dispensed a last dose from the container.
  • they may be reusable, for example, they may allow to replace a container by a new container or to refill the container.
  • Some devices and mechanisms according to the present disclosure may be fixed dose devices and mechanisms that only allow the dispensing of a fixed dose of the medicament or drug. Alternatively, they may be variable dose devices and mechanisms that allow for setting of a dose from a multitude of differing settable doses.
  • the mechanisms and devices according to the present disclosure may comprise a dose definition mechanism that allows a user to set the dose to be dispensed prior to dispensing.
  • the dose thereby may be set- table as a fixed dose only, for example for fixed dose devices or mechanisms.
  • the dose also may be set- table from a multitude of settable doses, such as for variable dose devices or mechanisms.
  • the doses may be settable as integer multiples of international units of the drug or medicament. They also may be settable as integer multiples of a fraction of said international units, such as integer multiples of half units.
  • Some mechanisms and devices according to the present disclosure may be single dose devices that allow dispensing of a dose from the container only once, so that the container is a single dose container. They also may be multiple dose devices that allow for a sequential dispensing of more than one dose from the same container, so that the container is a multi-dose container.
  • the drug delivery devices according to the present disclosure may be injection devices, such as needlebased injection devices.
  • Fig. 1 a first side view of a medicament delivery device according to the present disclosure having a dosing mechanism according to the present disclosure
  • Fig. 2 a second side view of the medicament delivery device
  • Fig. 3 a perspective view of the medicament delivery device with a cap of the medicament delivery device removed;
  • Fig. 4 a first side view of the medicament delivery device with the cap removed;
  • Fig. 5 a second side view of the medicament delivery device with the cap removed;
  • Fig. 6 a first cross-sectional side view of a medicament holder of the medicament delivery device with the cap attached to the medicament holder;
  • Fig. 7 a second cross-sectional side view of the medicament holder with the cap attached to the medicament holder;
  • Fig. 8 a side view of a cap end element of the cap
  • Fig. 9 a perspective view of the cap end element
  • Fig. 10 a perspective view of a cap body of the cap
  • Fig. 11 a perspective cross-sectional view of the cap body
  • Fig. 12 a perspective view of the medicament holder
  • Fig. 13 a side view of the medicament holder
  • Fig. 14 a perspective cross-sectional view of the medicament holder
  • Fig. 15 a cross-sectional view of the cap and the medicament holder in a plane perpendicular to a longitudinal axis;
  • Fig. 16 a perspective view of an outer housing of the dosing mechanism
  • Fig. 17 a side view of the outer housing of the dosing mechanism
  • Fig. 18 a perspective cross-sectional view of the outer housing
  • Fig. 19 a top view of the outer housing from a proximal end
  • Fig. 20 a detailed cross-sectional side view of the medicament holder attached to the dosing mechanism and the cap attached to the medicament holder;
  • Fig. 21 a cross-sectional top view of the medicament holder attached to the dosing mechanism and the cap attached to the medicament holder;
  • Fig. 22 an exploded view of the medicament delivery device and the dosing mechanism
  • Fig. 23 a cross-sectional side view of the dosing mechanism in a dose setting state with the dose set;
  • Fig. 24 a cross-sectional side view of the dosing mechanism in the dose setting state with a maximum dose set
  • Fig. 25 a cross-sectional side view of the dosing mechanism in a dose delivery state with the maximum dose set
  • Fig. 26 a perspective view of an inner housing of the dosing mechanism
  • Fig. 27 a cross-sectional perspective view of the inner housing of the dosing mechanism with a cut plane parallel to a longitudinal axis;
  • Fig. 28 a top view of the inner housing in a distal direction;
  • Fig. 29 perspective view of a piston rod guide of the dosing mechanism in a proximal direction
  • Fig. 30 a perspective view of the piston rod guide in a distal direction
  • Fig. 31 a side view of the piston rod guide
  • Fig. 32 a top view on a proximal end of the piston rod guide
  • Fig. 33 a cross-sectional side view of a first member, a second member and a friction brake of the dosing mechanism
  • Fig. 34 a cross-sectional side view of the first member, the second member and the friction brake in a cut plane perpendicular to a cut plane of Fig. 33;
  • Fig. 35 a perspective view of a nut of the dosing mechanism in a distal direction
  • Fig. 36 a perspective view of the nut in a proximal direction
  • Fig. 37 a perspective cross-sectional view of the nut in a cross-sectional plane parallel to a longitudinal axis
  • Fig. 38 a top view of a proximal end of the nut
  • Fig. 39 a top view of a distal end of the nut
  • Fig. 40 a perspective view of a driver of the dosing mechanism in a distal direction
  • Fig. 41 a perspective view of the driver in a proximal direction
  • Fig. 42 a cross-sectional perspective view of the driver
  • Fig. 43 a cross-sectional view of the driver, the nut, the inner housing, a dose member, and a piston rod of the dosing mechanism in a cut plane perpendicular to the longitudinal axis;
  • Fig. 44 a perspective view of a connector of the dosing mechanism in a proximal direction
  • Fig. 45 a perspective cross-sectional view of the connector in the proximal direction in a cut plane parallel to a longitudinal axis;
  • Fig. 46 a top view of a distal end of the connector
  • Fig. 47 a perspective view of a dose member of the dosing mechanism
  • Fig. 48 a side view of the dose member of the dosing mechanism
  • Fig. 49 a perspective cross-sectional view of the dose member in a cut plane parallel to a longitudinal axis
  • Fig. 50 a perspective view of a dose setting element of the dosing mechanism in a distal direction
  • Fig. 51 a perspective view of the dose setting element in a proximal direction
  • Fig. 52 a perspective cross-sectional view of the dose setting element in a cut plane parallel to a longitudinal axis
  • Fig. 53 a perspective view of a button ring of the dosing mechanism in a distal direction
  • Fig. 54 a perspective cross-sectional view of the button ring in a cut plane parallel to a longitudinal axis
  • Fig. 55 a perspective view of a button disc of the dosing mechanism in a distal direction
  • Fig. 56 a perspective cross-sectional view of the button disc in a cut plane parallel to a longitudinal axis
  • Fig. 57 a perspective view of a further embodiment of a cap end element of a cap attachable to the dosing mechanism
  • Fig. 58 a distal view of the further embodiment of the cap end element
  • Fig. 59 a side view of the further embodiment of the cap end element;
  • Fig. 60 a perspective view of a further embodiment of a medicament holder attachable to the dosing mechanism;
  • Fig. 61 a side view of the further embodiment of the medicament holder
  • Fig. 62 a detailed side view of the further embodiment of the medicament holder
  • Fig. 63 a perspective view of a piston rod of the dosing mechanism
  • Fig. 64 a first side view of the piston rod
  • Fig. 65 a second side view of the piston rod perpendicular to the view of Fig. 64;
  • Fig. 66 a perspective view of a piston bearing of the dosing mechanism
  • Fig. 67 a top view of the piston bearing.
  • Figs. 1 and 2 depict side views of a medicament delivery device 1 according to the present disclosure.
  • the medicament delivery device 1 is configured as an injection device, namely as a pen injection device.
  • the injection device 1 extends from a distal end 3 in a proximal direction 5 to a proximal end 2.
  • FIGs. 1 and 2 show the medicament delivery device 1 with a cap 10 attached to a dosing mechanism 100 of the medicament delivery device 1
  • Figs. 3 to 5 depict the medicament delivery device 1 with the cap 10 removed from the dosing mechanism 100.
  • Figs. 6 and 7 show cross-sectional side views of the medicament holder 40 attached to a housing 160 of the dosing mechanism 100 and the cap 20 attached to the medicament holder 40.
  • the medicament holder 40 is releasably attached to a proximal end of the dosing mechanism 100. It connects to the housing 160, namely to an outer housing 162 of the housing 160, via a connector 90.
  • the connector 90 is configured as a threaded connector.
  • the medicament holder 40 is configured to receive a medicament container 500, such as a cartridge, within an interior cavity and to attach the medicament container 500 to the housing 160.
  • the medicament container 500 comprises a container body 502 that surrounds a medicament compartment 503 containing the medicament.
  • a distal end of the medicament compartment 503 is sealed by a movable piston 510 and a proximal end of the medicament compartment 503 is sealed by a septum 504.
  • the piston 510 and the septum 504 are made from an elastic material, such as a rubber.
  • the medicament compartment 503 may also be integrally formed with the medicament holder 40.
  • the medicament holder 40 comprises two radially opposing windows 44 that allow for inspection of the medicament within the medicament holder 40.
  • the medicament holder 40 comprises a needle connector 42 that is configured to secure a cannula to the medicament holder 40.
  • a fluid connection between the medicament container 500 and the cannula is established by piercing the septum 504 provided at a proximal end of the medicament container 500.
  • the needle connector 42 is exemplarily configured as a threaded connector. With other embodiments, the needle connector 42 may also be configured as a bayonet lock, a Luer lock or the like.
  • the cap 10 With the drug delivery device 1 , the cap 10 is connected to the housing 160 of the dosing mechanism 100 via the medicament holder 40. The cap 10 thereby only engages with the medicament holder 40 but not with the housing 160 or any other part of the dosing mechanism 100.
  • a cap lock 85 acts between the cap 10 and the medicament holder 40. The cap lock 85 is configured to releasably hold the cap 10 at the medicament holder 40 in an axial direction.
  • the cap 10 On its outer surface, the cap 10 comprises a protruding part 32.
  • the protruding part 32 extends parallel to the longitudinal axis 7 and generally protrudes in the radial direction.
  • the protruding part 32 is configured to prevent rotation of the cap 10 and the dosing mechanism 100 attached to the cap 10 when being placed on a flat surface.
  • the protruding part 32 is configured as a longitudinal clip.
  • the cap 10 comprises a cap body 20 and a cap end element 30 that is attached to a proximal end of the cap body 20.
  • the cap end element 30 forms a first member of the cap 10 and the cap body 20 forms a second member of the cap 10.
  • the cap end element 30 is permanently glued to the cap body 20.
  • Figs. 8 and 9 depict the cap end element 30 and Figs. 10 and 11 depict the cap body 20.
  • the cap body 20 has a generally cylindrical shape and extends along a longitudinal axis 7.
  • the cap body 20 is configured as a sleeve that is open at both longitudinal ends.
  • the cap body 20 is configured as a machined part. It is made from metal.
  • the cap body 20 is configured as a lathed piece.
  • the cap end element 30 is made from a thermoplastic material. Exemplarily, it is configured as an injection molded part. The cap end element 30 closes the cap body 20 at its proximal end and forms an end cap of the cap body 20.
  • the cap end element 30 has a radially recessed section 29 that is received in an interior of the cap body 20.
  • the cap end element 30 with the recessed section 29 forms an inner part of the cap 10 and the cap body 20 forms an outer part of the cap 10 that partly surrounds the inner part.
  • the glue for attaching the cap end element 30 to the cap body 20 is provided between the recessed section 29 and the cap body 20.
  • the recessed section 29 comprises centering elements 31 that are configured as radially protruding ridges.
  • the ridges are orientated parallel to the longitudinal axis 7. They taper radially down towards the longitudinal axis 7 in a distal direction opposite the proximal direction 5 to facilitate attachment of the cap end element 30 to the cap body 20.
  • the cap 10 comprises a body alignment mechanism 33 that defines a single predefined rotational orientation of the cap end element 30 with respect to the cap body 20 after attachment of the cap end element 30 to the cap body 20.
  • the body alignment mechanism 33 comprises a first aligning part 34 provided at the cap end element 30 and a second aligning part 23 provided at the cap body 20.
  • the second aligning part 23 is configured as a radial recess, namely as a radial notch, provided in an outer wall of the cap body 20 and the first aligning part 34 is configured as a radial protrusion provided at an outer wall of the cap end element 30.
  • the second aligning part 23 is thereby accessible at an inside surface of the outer wall of the cap body 20 and the first aligning part 34 protrudes from an outer surface of the outer wall of the cap end element 30. Furthermore, the first aligning part 34 is provided at the recessed section 29 of the cap end element 30. Both the first aligning part 34 and the second aligning part 23 longitudinally extend along the longitudinal axis 7.
  • the body alignment mechanism 33 In addition to rotationally aligning the cap end element 30 with the cap body 20, the body alignment mechanism 33 also rotationally locks the cap end element 30 to the cap body 20. The body alignment mechanism 33 therefore also acts as a rotation lock between the cap body 20 and the cap end element 30.
  • the cap 10 comprises an additional body alignment mechanism that defines the rotational orientation of the cap body 20 with respect to the cap end element 30.
  • a first alignment feature of the additional body alignment mechanism is provided by a distally facing surface 28 of the cap end element 30 and a second alignment feature of the additional body alignment mechanism is formed by a proximally facing surface 25 of the cap body 20.
  • the first alignment feature is configured to engage with the second alignment feature when the cap end element 30 is attached to the cap body 20. Thereby, the first alignment feature and the second alignment feature are configured rotationally asymmetric with respect to the longitudinal axis 7.
  • the distally facing surface 28 of the first alignment feature fully extends around the longitudinal axis 7 and the proximally facing surface 25 of the second alignment feature likewise fully extends around the longitudinal axis 7.
  • the distally facing surface 28 and the proximally facing surface 25 are configured to contact each other over their whole surface only in a single relative rotational orientation.
  • the distally facing surface 28 thereby is exemplarily located around the circumference around the longitudinal axis 7 at varying axial positions along the longitudinal axis 7.
  • the proximally facing surface 25 is also located at varying axial positions along the longitudinal axis 7 around the circumference around the longitudinal axis 7.
  • Figs. 12 to 14 depict the medicament holder 40.
  • the medicament holder 40 has a generally cylindrical outer body. After attachment, the cap 10 covers the entire outer body of the medicament holder 40 except for a distal portion of the medicament holder 40.
  • the non-covered distal portion forms a cylindrical part. It comprises an outer surface 45 that is exposed in between the housing 160 of the dosing mechanism 100 and the cap 10 when the cap 10 is attached to the housing 160, see Figs. 1 and 2.
  • the cylindrical part forms a portion of the medicament holder 40 that has the largest extension in the radial direction.
  • a cap alignment mechanism 80 acts between the cap 10 and the housing 100.
  • the cap alignment mechanism 80 is configured to define a single rotational orientation in which the cap 10 is attachable to the housing 160. With the medicament delivery device 1 , the cap alignment mechanism acts between the cap 10 and the medicament holder 40.
  • the medicament holder 40 thereby comprises a first aligning part 60 of the cap alignment mechanism 80 that interacts with a second aligning part 35 of the cap alignment mechanism 80 to define the rotational orientation between the cap 10 and the housing 160.
  • the first aligning part 60 is located at the proximal end of the medicament holder 40 and distally from the needle connector 42. Furthermore, the first aligning part 60 is formed at a radial step of the medicament holder 40. The radial step connects a radially narrower section of the medicament holder 40 with a radially wider section, whereby the radially narrower section is located in the proximal direction from the radially wider section.
  • the first aligning part 60 is configured as a radial depression on the outer surface of the body of the medicament holder 40.
  • the radial depression is open along the longitudinal axis 7 in both the proximal direction 5 and the distal direction. In the proximal direction 5, the radial depression terminates at the radial step and, in the distal direction, the radial depression terminates at one of the windows 44 provided in the outer body of the medicament holder 40.
  • the first aligning part 60 comprises a lead-in taper that narrows in the distal direction.
  • the lead-in taper is exemplarily formed by first sidewalls 64 that delimit the first aligning part 60 in the circumferential direction around the longitudinal axis 7.
  • the sidewalls 64 are tilted with respect to the longitudinal axis 7 and have a first taper angle 81 with respect to the longitudinal axis 7.
  • the second aligning part 35 of the cap alignment mechanism 80 is provided at the cap end element 30. It is located at an inner surface of the cap end element 30. Exemplarily, it is configured as a protrusion that protrudes from the inner surface. Furthermore, the second aligning part 35 is located at a proximal end of the cap 10.
  • the second aligning part 35 comprises a lead-in taper that narrows in the distal direction.
  • Second sidewalls 37 of the second aligning part 35 are tilted with respect to the longitudinal axis 7.
  • the second sidewalls 37 have a second taper angle 82 with the longitudinal axis 7. Both the first taper angle 81 and the second taper angle 82 are essentially constant along the longitudinal lengths of the first sidewalls 64 and the longitudinal lengths of the second sidewalls 37, respectively.
  • Fig. 15 depicts a cross-sectional view of the cap 10 and the medicament holder 40 in a plane perpendicular to a longitudinal axis 7 through the cap alignment mechanism 80 and the body alignment mechanism 33.
  • a radially outwardly facing surface 62 of the first aligning part 60 faces a radially inwardly facing surface 36 of the second aligning part 35.
  • the surfaces 62, 36 are generally aligned parallel to each other.
  • the first sidewalls 64 of the first alignment feature have an undercut in the radial direction 61 .
  • the first sidewalls 37 of the second aligning part 35 comprise an undercut in the radial direction 61 .
  • the recessed section 29 of the cap end element 30 forms an inner part 39 received within the cap body 20 and the protruding part 32 forms an outer part 38 that is positioned outside the cap body 20.
  • the inner part 39 and the outer part 38 are connected by the first aligning part 34 of the body alignment mechanism 33.
  • the first aligning part 34 is thereby located within the notch formed by the second aligning part 23 of the body alignment mechanism 33.
  • the cap lock 85 comprises a first cap lock element 47 at the medicament holder 40 that engages with a second cap lock element 21 provided at the cap 10, as shown in Fig. 1 1 .
  • the first cap lock element 47 is configured as a radial protrusion located on an outer surface of the medicament holder 40.
  • the first cap lock element 47 is elongated in the circumferential direction and has a length along the circumferential direction that is larger than a width along the longitudinal axis 7. The length thereby is limited to less than a full revolution, namely to less than half a full revolution, such as less than a quarter of a full revolution.
  • the second cap lock element 21 is configured as a radial depression on an inside surface of the cap 10, namely on an inside surface of the cap body 20.
  • the second cap lock element 21 is located along a circumferential direction and has a length in the circumferential direction that is larger than a width along the longitudinal axis 7. The second cap lock element 21 thereby extends over a full revolution around the longitudinal axis 7.
  • the first cap lock element 47 engages with the second cap lock element 21 to axially retain the cap 10 on the medicament holder 40.
  • the medicament holder 40 comprises a first connection element 41 of the connector 90 that connects the medicament holder 40 releasably to the housing 160, namely to the outer housing 162.
  • the first connection element 41 thereby is located at the non-covered distal portion of the medicament holder 40 that is bounded by the outer surface 45.
  • Figs. 16 to 19 depict the outer housing 162 of the housing 160.
  • the outer housing 162 is configured as a generally cylindrical part that extends parallel to the longitudinal axis 7. It is configured as a sleeve that is open at both longitudinal ends. Furthermore, it has a continuous bore that extends over its entire longitudinal length.
  • the outer housing 162 comprises a second connection element 163 of the connector 90.
  • the second connection element 163 is configured as a male connector and the first connection element 41 provided at the medicament holder 40 is configured as a female connector.
  • the second connection element 163 is configured as an outer thread and the first connection element 41 is configured as a corresponding inner thread.
  • a blocking mechanism 70 rotationally fixes the medicament holder 40 with respect to the housing 160 when the cap 10 is attached to the medicament holder 40.
  • the blocking mechanism 70 comprises a first blocking element 50 that is provided at the medicament holder 40 and a second blocking element 167 that is provided at the housing 160, namely at the outer housing 162.
  • the first blocking element 50 is provided at an inner surface of the medicament holder 40 and the second blocking element 167 is provided at an outer surface of the outer housing 162.
  • the first blocking element 50 is configured as a radial protrusion that extends from the inner surface of the medicament holder 40 in the radial direction and the second blocking element 167 is configured as a radial depression within the outer surface of the outer housing 162.
  • the first blocking element 50 may instead be configured as the depression and the second blocking element 167 may be configured as the protrusion.
  • the first blocking element 50 extends parallel to the longitudinal axis 7 and has a length along the longitudinal axis 7 that is larger than a width perpendicular to the longitudinal axis 7. It thereby has a rounded outer surface that is rounded around an axis running parallel to the longitudinal axis 7. With the medicament holder 40, the first blocking element 50 is configured as a longitudinal cylindrical section.
  • the first blocking element 50 is located at a flexible element 52 and configured to flex in a radial direction perpendicular to the longitudinal axis 7.
  • the flexible element 52 is formed within the outer wall of the medicament holder 40. It forms a free-standing structure that is surrounded by a gap 53. With a first end 51 , the flexible element 52 is fixed to the medicament holder 40 while the first blocking element 50 is located at an opposing second end 53 of the flexible element 52. The second end 53 thereby is freestanding.
  • the flexible element 52 comprises a flexing portion 56 that has a lower flexural stiffness than the remaining portion of the flexible element 52.
  • the flexing portion 56 is configured as a section of the flexible element 52 that as a reduced thickness in the radial direction compared to the remaining portion of the flexible element 52. It comprises a circumferential groove provided on a surface of the flexible element 52. Exemplarily, the circumferential groove is provided at an outer surface of the flexible element 52. With other embodiments, the circumferential groove may also be provided at an inner surface of the flexible element 52.
  • the first blocking element 50 is located within a protruding axial section 43 of the medicament holder 40 that is connected to a recessed axial section 48 by a step 46.
  • the recessed axial section 48 is located in the proximal direction 5 from the protruding axial section 43.
  • a radial extent of the protruding axial section 43 is larger than a radial extent of the recessed axial section 48 and also larger than a radial extent of the remaining part of the medicament holder 40 in the proximal direction 5.
  • the flexible element 52 extends from the recessed axial section 48 over the step 46 to the protruding axial section 43. It thereby comprises parts of the outer surfaces of the recessed axial section 48, the step 46, and the protruding axial section 43.
  • the second blocking element 167 is located at a proximal end of the outer housing 162. It thereby is located in between the proximal end and the second connection element 163 of the connector 90. Furthermore, it is axially spaced from the second connection element 163 in the proximal direction 5.
  • the second blocking element 167 has a first side surface 166 and a second side surface 168.
  • the second side surface 168 delimits the second blocking element 167 in a circumferential direction 6 and the first side surface 167 delimits the second blocking element 167 in a further circumferential direction opposite the circumferential direction 6.
  • the first side surface 166 thereby is steeper than the second side surface 168.
  • Fig. 20 depicts a cross-sectional side view of the medicament holder 40 attached to the housing 160 and with the cap 20 attached to the medicament holder 40, shown in a cut plane parallel to the longitudinal axis 7.
  • Fig. 21 depicts a cross-sectional front view of the medicament holder 40 and the cap 20 in a plane perpendicular to the longitudinal axis 7.
  • the cap 20 interlocks the first blocking element 50 in engagement with the second blocking element 167 when the cap 20 is fully attached to the medicament holder 40. It thereby blocks the first blocking element 50 from bending away from the second blocking element 167 in the radial direction.
  • the cap 20 engages with a surface of the first blocking element 50 that faces away from the second blocking element 167.
  • the surface forms part of the flexible element 52 so that the attached cap 20 also engages with the flexible element 52.
  • An inner surface of the cap 20 thereby is shaped complementarily to the stepped portion of the outer surface of the medicament holder 40, the stepped portion comprising the step 46, at least parts of the protruding axial section 43 and at least parts of the recessed axial section 48.
  • the blocking mechanism 70 comprises a further first blocking element 50 of the medicament holder 40 that is located opposite the first blocking element 50 and a further second blocking element 167 of the outer housing 162 that is located opposite the second blocking element 167.
  • the first blocking elements 50 and the second blocking elements 167 are each identical in form and function.
  • the blocking mechanism 70 is configured to provide an audible and/or tactile feedback when the medicament holder 40 is being fully attached to the housing 160. Engagement of the first blocking elements 50 with the second blocking elements 167 thereby provides the feedback, exemplarily by producing a click.
  • the blocking mechanism 70 is configured to provide an audible and/or tactile feedback when the medicament holder 40 is moved out of its fully attached position with respect to the housing 160. This feedback is generated by the first blocking element 50 hitting the first side surface 166 of the second blocking element 167 when the medicament holder 40 is rotated out of its fully attached position.
  • the dosing mechanism 100 comprises an actuation unit 300 with a dose setting element 310 and a button 330 at its distal end 3.
  • the dose setting element 310 has a generally ring-like shape outer surface that comprises a gripping structure 312.
  • the dose setting element 310 is configured to be gripped by a user at the gripping structure 312 and to be rotated by the user around the longitudinal axis 7 of the medicament delivery device 1 .
  • a corresponding marking 252 is shown in a window 164 in the outer housing 160 of the dosing mechanism 100.
  • the user rotates the dose setting element 310 back towards its zero position.
  • the button 330 is configured to be pushed by the user in the proximal direction 5. This transfers the medicament delivery device 1 from a dose setting state into a dose delivery state.
  • Fig. 22 depicts an exploded perspective view of the medicament delivery device 1 and the dosing mechanism 100.
  • Fig. 23 depicts a cross-sectional side view of the dosing mechanism 100 in a plane parallel to the longitudinal axis 7, whereby the dosing mechanism 100 is in a dose setting state with no dose set.
  • the dosing mechanism 100 comprises a piston rod 110 that has a piston bearing 120 located at its proximal end.
  • the piston rod 110 is configured to move into the medicament holder 40 and to push the piston 510 in the proximal direction 5 to deliver the medicament.
  • the piston rod 110 thereby pushes on the piston 503 via the piston bearing 120.
  • the piston 503 has a blind hole at its distal end face and the piston bearing 120 comprises a pin at its front surface that extends into the blind hole of the piston 503. Furthermore, the blind hole of the piston 503 has a structured radial surface, namely a threaded radial surface. The piston 503 thereby is attached to the pin of the piston bearing 120 via a friction fit provided by the radial surface.
  • the piston bearing 120 is configured as a part separate from the piston rod 110 and the piston bearing 120 is connected to the piston rod 110 by a connector. With other embodiments, the piston bearing 120 may also be formed integrally with the piston rod 110.
  • the working principle of the dosing mechanism 100 is generally described in document US20060258988A1 .
  • the disclosure of that working principle in document US20060258988A1 is incorporated into the present disclosure by reference in its entirety.
  • the piston rod 1 10 is rotationally fixed with respect to the housing 160. It is thereby guided within a piston rod guide 130 that is configured as a part separate from the housing 160 and that is rotationally fixed with respect to the housing 160 during both dose setting and dose delivery.
  • the piston rod 1 10 is permanently rotationally fixed with respect to the piston rod guide 130.
  • the piston rod guide 130 has a central through hole 134 that receives the piston rod 1 10.
  • the through hole 134 has a rotationally asymmetric radial cross-section and the outer surface of the piston rod 1 10 has a corresponding rotationally asymmetric radial cross-section. This provides an axial lock that rotationally fixes the piston rod 1 10 to the piston rod guide 130 while allowing relative axial movement between the piston rod 1 10 and the piston rod guide 130.
  • the housing 160 comprises an inner housing 180 that is received within the outer housing 162.
  • the inner housing 180 is fully received within the outer housing 162.
  • the outer housing 162 is configured as a metal part, such as a lathed metal part
  • the inner housing 180 is made from a plastic material, such as from a thermoplastic material.
  • the inner housing 180 may be configured as an injection molded part.
  • the inner housing 180 is permanently rotationally and axially fixed to the outer housing 162 so that the inner housing 180 and the outer housing 162 form a single functional component.
  • the piston rod guide 130 is connected to the inner housing 180 and may take up two axial positions with respect to the housing 160, a distal position and a proximal position.
  • a first biasing member 150 acts between the housing 160 and the piston rod guide 130 and biases the piston rod guide 130 in the proximal direction 5 away from the housing 160 into the proximal position.
  • proximal movement of the piston rod guide 130 is limited by an axial stop 95 that comprises a first stop member at the inner housing 180 and a second stop member at the piston rod guide 130.
  • the stop members engage with each other when the piston rod guide 130 reaches the proximal position and restrict further proximal movement of the piston rod guide 130. In the proximal position, the piston rod guide 130 is free to rotate with respect to the housing 160, while it is rotationally fixed with respect to the housing 160 in the distal position.
  • the piston rod guide 130 is in the proximal position when the medicament holder 40 comprising the medicament container 500 is removed from the housing 160.
  • the piston rod guide 130 is pushed in the distal direction by the medicament container 500 when the medicament holder 40 with the medicament container 500 is attached to the housing 160.
  • the piston rod 1 10 is also rotationally locked with respect to the housing 160 as long as the medicament holder 40 with the medicament container 500 is attached to the housing 160.
  • the dosing mechanism 100 further comprises a nut 200 that is configured as a generally cylindrical hollow member and that at least partially surrounds the piston rod 1 10.
  • a threaded connection 1 12 acts between the piston rod 110 and the nut 200. With the drug delivery device 1 , the nut 200 is engaged with the piston rod 110 via the threaded connection 112. Generally speaking, the nut 200 forms a threaded part and the threaded connection 112 acts between the piston rod 110 and the threaded part.
  • the nut 200 is coupled to a connector 270 of the dosing mechanism 100 via a rotation lock 273.
  • the nut 200 thereby is rotationally fixed and axially movable with respect to the connector 270.
  • the connector 270 is axially fixed to the button 330 via an axial lock 335.
  • the button 330 comprises a button disc 332 and a button ring 340 that are axially fixed with respect to each other.
  • the button ring 340 is rotatable with respect to the button disc 332.
  • the button ring 340 may also be rotationally fixed with respect to the button disc 332.
  • the button disc 332 and the button ring 340 may be configured as a single part.
  • the button disc 332 is located at the distal end 3 of the dosing mechanism 100 and the button ring 340 is attached on a proximal side of the button disc 332.
  • the button ring 340 thereby surrounds the axial lock 335 provided between the button 330 and the connector 270.
  • a bearing 360 is located between the button 330 and the connector 270.
  • the bearing 360 is configured as a pivot bearing with two opposing bearing surfaces that are orientated perpendicular to the longitudinal axis 7.
  • the bearing 360 exemplarily comprises a ball bearing and the bearing surfaces are part of two washers that are located at either side of the ball bearing along the longitudinal axis 7.
  • the bearing 360 is configured to facilitate rotation of the connector 270 with respect to the button 330 when the button 330 is pushed in the proximal direction against the connector 270.
  • the bearing 360 surrounds a distal cylindrical part 277 of the connector 270. In the proximal direction, it axially rests on a shoulder 278 provided at the outside surface of the distal cylindrical part 277.
  • the button ring 340 radially surrounds the bearing 360. A proximal inner surface of the button ring 340 rests against the distal part of the bearing 360, namely against the distal washer of the bearing 360.
  • the dosing mechanism 100 further comprises a dose member 250 that is configured as a generally cylindrical hollow member.
  • the dose member 250 surrounds the nut 200 and the piston rod 110. Furthermore, an outer surface of the dose member 250 is located directly at an inner surface of the housing 160, namely at an inner surface of the inner housing 180.
  • a threaded connection 182 acts between the dose member 250 and the housing 160.
  • the dose member 250 engages the housing 160 via the threaded connection 182.
  • the threaded connection 182 comprises an outer thread on an outer surface of the dose member 250 that engages with an inner thread on an inner surface of the inner housing 180.
  • the dose member 250 forms a threaded part and the threaded connection 182 acts between the threaded part and the housing 160.
  • the dose member 250 is permanently rotationally and axially fixed with respect to the dose setting element 310 by a connector 251 .
  • the connector 251 is configured as a snap-fit connector.
  • the dosing mechanism 100 further comprises a driver 230 that is configured as a generally cylindrical hollow member and that at least partially surrounds the nut 200. Furthermore, the driver 230 is located radially in between the nut 200 and the dose member 250.
  • a threaded connection 255 acts between the driver 230 and the dose member 250.
  • the driver 230 thereby is threadedly engaged with the dose member 250 via the threaded connection 255.
  • the threaded connection 255 comprises an outer thread on an outer cylindrical surface of the driver 230 that engages with an inner thread on an inner cylindrical surface of the dose member 250.
  • the driver 230 is rotationally fixed to the housing 160 via a rotation lock 202.
  • the rotation lock 202 allows longitudinal movement of the driver 230 with respect to the housing 160.
  • the dosing mechanism 100 further has a clutch 275 that acts between the nut 200 and the dose member 250.
  • the clutch 275 rotationally locks the nut 200 to the dose member 250 in a closed state and allows relative rotation between the nut 200 and the dose member 250 in an opened state.
  • the clutch 275 rotationally locks the nut 200 to the dose member 250 and, during dose delivery, the clutch 270 rotationally decouples the nut 200 from the dose member 250.
  • the clutch 275 is exemplarily provided between the connector 270 and the dose setting element 310. It comprises radial teeth on an outer surface of the connector 270 that engage with corresponding radial teeth on an inner surface of the dose setting element 310 when the clutch 275 in the closed state.
  • the clutch 275 is configured to transfer from the closed state into the opened state by axially moving the connector 270 with respect to the dose setting element 310.
  • the clutch 275 is biased into its closed state.
  • a second biasing member 152 acts between the connector 270 and the dose setting element 310 and biases the connector 270 in the distal direction with respect to the dose setting element 310.
  • the second biasing element 152 is configured as a compression spring.
  • the second biasing element 310 is provided in between the dose member 250 and the connector 270 and engages with both the dose member 250 and the connector 270.
  • Proximal movement of the button 330 moves the connector 270 in the proximal direction 5 against the force of the second biasing member 152. This transfers the clutch 275 from its closed state into its opened state.
  • the dose setting element 310 may also be rotationally and axially fixed with respect to the button 330.
  • the button 330 and the dose setting element 310 then may be permanently axially and rotationally fixed to the connector 270 instead of the connection via the axial lock 335.
  • the dose setting element 310 and button 330 may be connected to the connector 270 via the axial lock 335.
  • the dosing mechanism 100 then may comprise an additional clutch that rotationally locks the dose setting element 310 and the button 330 to the dose member 250 during dose setting and rotationally decouples the dose setting element 310 and the bottom 330 from the dose member 250 during dose delivery.
  • the additional clutch may be transferred into its opened state by pushing the button 330 in the proximal direction 5.
  • the clutch 275 then may act between the dose member 250 and the connector 270, but not between, on the one hand, the button 330 and the dose setting member 310 and, on the other hand, the dose member 250 and the connector 270.
  • both the nut 200 and the dose member 250 are rotationally fixed to the dose setting element 310. Rotation of the dose setting element 310 then causes the nut 200 and the dose member 250 to move axially with respect to the piston rod 110 and the housing 160 due to, on the one hand, the threaded connection 112 between the nut 200 and the piston rod 110 and, on the other hand, the threaded connection 182 between the dose member 250 and the housing 160.
  • the nut 200 and the dose member 250 both move axially in the distal direction.
  • a set dose may be decreased by rotating the dose setting element 310 in an opposite direction as during dose setting.
  • a pitch of the threaded connection 112 is different from a pitch of the threaded connection 182 so that the nut 200 and the dose member 250 travel differing axial distances upon rotation by the same angle.
  • the pitch of the threaded connection 112 is smaller than the pitch of the threaded connection 182 and the dose member 250 travels a larger axial distance than the nut 200.
  • a pitch of the threaded connection 255 acting between the rotationally fixed driver 230 and the dose member 250 is adapted to cause the driver 230 to axially move together with the nut 200 along the longitudinal axis 7 upon rotation of the dose setting element 310 during dose setting.
  • the pitch of the threaded connection 255 thereby is at most a difference between a maximum pitch of the threaded connection 112 and a minimum pitch of the threaded connection 182.
  • the maximum pitch of the threaded connection 112 thereby is given by an upper limit of fabrication tolerances of the threaded connection 112 and the minimum pitch of the threaded connection 182 is given by a lower limit of fabrication tolerances of the threaded connection 182. This prevents the nut 200 from advancing faster in the distal direction than the driver 230 and avoids blocking movement of the nut 200 by the driver 230.
  • Fig. 24 depicts a cross-sectional side view of the dosing mechanism 100 after having set a maximum dose.
  • the dose member 250 has been screwed out of the housing 160 in the distal direction and the dose setting element 310 and the button 330 have moved together with the dose member 250 in the distal direction.
  • the nut 200 has been screwed along the piston rod 110 in the distal direction and the driver 230 has translated together with the nut 200 in the distal direction without rotation.
  • the nut 200 and the dose member 250 have performed at least one, namely at least two full revolutions around the longitudinal axis 7.
  • the maximum dose is set by rotating the nut 200 and the dose member 250 by three full revolutions around the longitudinal axis 7.
  • a latching mechanism 192 acts between the nut 200 and the housing 160.
  • the nut 200 thereby rotation- ally couples the dose setting element 310 and the dose member 250 to the latching mechanism 192.
  • the latching mechanism 192 also acts as a dose definition mechanism that defines discrete rotational positions of the nut 200 and the dose setting element 310 and the dose member 250, wherein the discrete rotational positions correspond to settable doses.
  • the latching mechanism 192 comprises a first latching part 223 that is rotationally fixed to the nut 200 and a second latching part 193 that is rotationally fixed to the housing 160.
  • One of the first and second latching part 223, 193, namely the second latching part 193, comprises longitudinal webs that are circumferentially distributed around the longitudinal axis 7 and the other one of the first and second latching part 123, 193, namely the first latching part 223, comprises a flexible element engaging with the longitudinal webs upon rotation of the first latching part 223 with respect to the second latching part 193.
  • the first latching part 223 is additionally axially fixed to the nut 200 and the second latching part 193 is axially fixed to the housing 160.
  • the first latching part 223 is integrally formed with the nut 200 and the second latching part 193 is integrally formed with the housing 160, namely with the inner housing 180.
  • the second latching part 193 is thereby provided at an inner section 190 of the inner housing 180.
  • the inner section 190 comprises the second latching part 193 on a cylindrical inner surface.
  • the inner section 190 is configured as a hollow cylindrical portion of the inner housing 180 and extends from a proximal end of the inner housing 180 in the distal direction.
  • the inner section 190 is surrounded by an outer wall of the inner housing 180, whereby the outer wall comprises the threaded connection 182 to the dose member 250.
  • the dose member 250 moves within an annular space in between the outer wall of the inner housing 180 and the inner section 190.
  • the inner section 190 has an open distal end and the nut 200 and the driver 230 extend through the open distal end.
  • Relative rotation of the nut 200 with respect to the housing 160 during dose setting causes the first latching part 223 to rotate with respect to the second latching part 193 and to thereby provide an audible and/or tactile feedback to the user.
  • the feedback comprises a click each time a dose has been set.
  • the feedback is produced by the first latching part 223 engaging with consecutive grooves in between the webs of the second latching part 193.
  • the rotation lock 202 that rotationally fixes the driver 230 to the housing 160 comprises at least one first lock element 241 that is rotationally fixed to the driver 230 and at least one second lock element that is rotationally fixed to the housing 160.
  • the rotation lock 202 is configured as a splined connection that extends along the longitudinal axis 7.
  • One of the first lock element 241 and the second lock element is configured as a longitudinal groove and the other one of the first lock element 241 and the second lock element is configured as a corresponding longitudinal ridge engaging with the longitudinal groove.
  • the at least one second lock element is provided by the second latching part 193 of the latching mechanism 192.
  • the second lock element is thereby formed by a longitudinal groove between two of the longitudinal webs of the second latching part 193.
  • An end stop 235 prevents setting of a dose that exceeds the maximum dose.
  • the end stop 235 acts between the dose member 250 and the driver 230.
  • the end stop 235 limits axial movement of the driver 230 with respect to the dose member 250. It is configured as an axial stop and stop surfaces of the end stop 235 engage by axially moving towards each other.
  • the end stop 235 is located at a distal end of the threaded connection 255.
  • the end stop 235 comprises a radial protrusion on the outer surface of the driver 230 that engages with a radial step formed at an inner surface of the dose member 250.
  • the radial step on the inner surface of the dose member 250 is formed at a distal end of an inner sleeve of the dose member 250, whereby the inner sleeve carries the threaded connection 255 to the driver 230.
  • the dosing mechanism 100 After having set the dose, the dosing mechanism 100 is configured to transfer from the dose setting state to a dose delivery state upon a user pushing the button 330 in the proximal direction 5.
  • Fig. 25 depicts the dosing mechanism 100 in the dose delivery state prior to delivering the maximum dose.
  • the button 330 has moved in the proximal direction 5 with respect to the dose setting element 310 until the button 330 axially engages with the dose setting element 310 via the bearing 360.
  • the bearing 360 thereby rests against in inner distal surface of the dose setting element 310.
  • the bearing 360 and the button ring 340 surrounding the bearing 360 are received in a distal open cavity of the dose setting element 310.
  • Proximal movement of the button 330 also moves the connector 270 in the proximal direction 5 with respect to the dose setting element 310 via the axial lock 335. This opens the clutch 275 so that the dose member 250 and the dose setting element 310 are allowed to rotate with respect to the connector 270 and the nut 200.
  • proximal movement of the button 330 then pushes the dose member 250 in the proximal direction 5 and the proximal force exerted on the button 330 is transferred to the dose member 250 via the bearing 360. Due to the threaded connection 182, the dose member 250 rotates back into the housing 160. Proximal movement and rotation of the dose member 250 also causes proximal movement of the driver 230 via the threaded connection 255. Since the driver 230 is prevented from rotating by the rotation lock 202 it is screwed in the distal direction with respect to the dose member 250 due to the threaded connection 255.
  • the driver 230 is axially coupled to the nut 200 in the proximal direction 5 and configured to push the nut 200 in the proximal direction 5, as it is further detailed below. Since the nut 200 is rotationally decoupled from the dose member 250 when the clutch 275 is in its opened state, it does not receive a torque from the rotating dose member 250. Rotation of the dose member 250 with respect to the nut 200 is further facilitated by the axial lock 335 that allows rotation between the connector 270 and the button 330 and the bearing 360.
  • the latching mechanism 192 acts as a rotation brake during dose delivery that prevents the nut 200 from rotating with respect to the piston rod 1 10. This locks the threaded connection 1 12 between the nut 200 and the piston rod 1 10 so that the piston rod 1 10 is forced to move axially together with the nut 200 in the proximal direction 5.
  • the piston rod 110 then moves into the medicament holder 40 and the medicament container 500 and advances the piston 510 in the proximal direction 5 to expel the medicament from the medicament compartment 503.
  • the dosing mechanism 100 comprises a zero dose stop that stops axial movement of the piston rod 110 in the proximal direction 5 at the end of dose delivery.
  • the zero dose stop acts between the dose member 250 and the housing 160. It limits proximal movement of the dose member 250 with respect to the housing 160.
  • It is configured as an axial stop with stop elements that engage with each other by moving towards each other along the longitudinal axis 7.
  • the stop elements comprise stop surfaces that are orientated generally perpendicular, such as perpendicular, to the longitudinal axis 7.
  • the zero dose stop is formed at the dose setting element 310 and the housing 160, exemplarily the outer housing 162.
  • a first stop element is thereby formed at the dose setting element 310 and a second stop element is formed at the housing 160.
  • the first stop element is provided by the proximal end surface of the dose setting element 310 and the second stop element is provided by the distal end surface of the housing 160, exemplarily at the outer housing 162, namely by the distal end surface of the outer housing 162.
  • the proximal end surface of the dose setting element 310 and the distal end surface of the inner housing 180 are spaced apart from each other in the zero dose state.
  • the second stop element may also be formed at the inner housing 180.
  • the second stop element may be formed by a distal end surface of the inner housing 180.
  • the dosing mechanism 100 further comprises a last dose stop 114 that prevents setting of a dose that is larger than a remaining amount of medicament in the medicament compartment 503.
  • the last dose stop 114 acts between the piston rod 110 and the nut 200. It comprises a radial protrusion on the outer surface of the piston rod 110, the radial protrusion being located at the distal end of the outer thread of the threaded connection 112 between the piston rod 110 and the nut 200.
  • the last dose stop 114 further comprises a radial step on the inner surface of the nut 200, whereby the step is provided at the distal end of the inner thread of the threaded connection 112.
  • the step protrudes radially inwardly and engages with the protrusion on the distal end of the piston rod 110 when the nut 200 reaches the distal end of the piston rod 110 during dose setting.
  • a zero dose position of the nut 200 with respect to the piston rod 110 sequentially moves in the proximal direction 5 along the piston rod 110.
  • a length of the outer thread on the piston rod 110 is adapted to cause engagement of the last dose stop 114 and to stop distal movement of the nut 200 when a set dose equals the remaining dose in the medicament compartment 503.
  • the pitch of the threaded connection 112 between the piston rod 110 and the nut 200 may also be larger than the pitch of the threaded connection 182 between the housing 160 and the dose member 250.
  • the pitch of the threaded connection 112 may also equal the pitch of the threaded connection 182.
  • the driver 230 may be connected to the dose member 250 by an axial lock that axially fixes the driver 230 to the dose member 250 while allowing relative rotation of the driver 230 with respect to the dose member 250.
  • Figs. 26 to 28 depict the inner housing 180.
  • the inner housing 180 is formed as a generally cylindrical hollow part. It comprises an outer section 181 that is integrally formed with the inner section 190.
  • the outer section 181 forms an outer wall of the inner housing 180.
  • An inner surface of the inner section 190 comprises the inner thread of the threaded connection 182. The inner thread thereby extends over the complete length of the inner surface along the longitudinal axis 7.
  • the inner housing 180 comprises a locking element of a first axial lock 165 that axially locks the inner housing 180 with respect to the outer housing 162 in the distal direction.
  • the axial lock 165 is configured as a snap-lock that allows insertion of the inner housing 180 into the outer housing 162 in the proximal direction 5 and blocks distal movement of the inner housing 180 out of the outer housing 162 in the distal direction after engagement.
  • the locking element of the inner housing 180 thereby engages with a corresponding locking element provided on an inside surface of the outer housing 162, see Fig. 18.
  • the locking element of the inner housing 180 thereby is configured as a radial protrusion on the outer surface of the inner housing 180.
  • the protrusion has a radial surface that is orientated parallel to a radial plane perpendicular to the longitudinal axis 7 at its distal end and a beveled surface at its proximal end to facilitate insertion of the inner housing 180 into the outer housing 162.
  • the locking element of the outer housing 162 is configured as a circumferential groove with a radial end surface in the distal direction that is perpendicular to the longitudinal axis 7. The groove thereby covers the entire circumference of the inner surface of the outer housing 162.
  • Movement of the inner housing 180 with respect to the outer housing 162 in the proximal direction is restricted by an axial stop.
  • the axial stop is formed between a proximal end surface 183 of the inner housing 180 and a distally facing proximal end surface 170 of the outer housing 162.
  • the end surface 170 thereby delimits an interior cavity that receives the inner housing 180 in the proximal direction 5.
  • a first rotational lock between the inner housing 180 and the outer housing 162 is provided by a protrusion 184 at the proximal end surface 183 of the inner housing 180 and a corresponding recess 171 at the end surface 170 of the outer housing 162.
  • the protrusion 184 and the recess 171 are thereby rotationally asymmetric with respect to the longitudinal axis 7.
  • a second rotational lock between the inner housing 180 and the outer housing 162 is provided by a protrusion 185 at the outer surface of the inner housing 180 that engages with a corresponding recess 172 provided at the inner surface of the outer housing 162.
  • the recess 172 thereby is configured as a notch at a proximal edge of the window 164.
  • the inner housing 180 is made from a transparent material and covers the window 164 from the inside.
  • the protrusion 185 then radially protrudes into the recess 172 of the window 164.
  • the inner housing 180 comprises first stop members 186 of the axial stop 95 that limits axial movement of the piston rod guide 130 in the proximal direction 5.
  • the first stop members 186 are configured as flexible snap hooks that extend from the inner housing 180 in the proximal direction 5.
  • the snap hooks have a cylindrical shape.
  • Figs. 29 to 32 depict the piston rod guide 130.
  • the piston rod guide 130 has a second stop member 133 of the axial stop 95 that is configured to engage with the first stop members 186.
  • the second stop member 133 is configured as a cylindrical protrusion that extends from the axial stop 95 in the distal direction. It is placed radially inward from the first stop members 186. The snap hooks formed by the first stop members 186 then engage with a radial outer rim provided at a distal end of the second stop member 133 when the piston rod guide 130 is in its proximal position with respect to the housing 160.
  • the inner housing 180 comprises a first locking member 188 of a rotation lock that acts between the housing 160 and the piston rod guide 130.
  • the first locking member 188 is configured as a longitudinally toothed radial surface at the proximal end of the inner housing 180. The first locking member 188 thereby surround the axial lock 95.
  • the piston rod guide 130 comprises a second locking member 135 of the rotation lock.
  • the second locking member 135 comprises longitudinal teeth that are configured to engage with the toothed circumferential section of the inner housing 180. The teeth thereby extend from the piston rod guide 130 in the distal direction. They are placed radially outwards from the second stop member 133.
  • the dosing mechanism 1 10 comprises a re-setting member that is configured to move the piston rod 1 10 back into the housing 160 after the medicament holder 40 has been detached from the housing 160.
  • the resetting member is formed by the piston rod guide 130. A rotation of the piston rod guide 130 with respect to the housing 160 when the medicament holder 40 is detached from the housing 160 causes the piston rod 1 10 to move relative to the housing 160.
  • the piston rod guide 130 Since the piston rod 1 10 is rotationally fixed to the piston rod guide 130, the rotation of the piston rod guide 130 forces the piston rod 1 10 to also rotate. This screws the piston rod 1 10 along the threaded connection 182 between the piston rod 1 10 and the nut 200. The user then may reset the dosing mechanism 100 by rotating the piston rod guide 130 when the piston rod guide 130 is in its proximal position.
  • the piston rod guide 130 comprises a gripping structure 132 on its outer circumference. The gripping structure 132 thereby is located at a proximal end of the piston rod guide 130.
  • the threaded connection 182 acting between the piston rod 1 10 and the nut 200 may be configured as a non-self-locking threaded connection.
  • the piston rod 1 10 then may be forced to helically move along the threaded connection 182 by pushing it towards the housing 160. This allows a user to reset the dosing mechanism 100 by manually pushing the piston rod 1 10 back into the housing 160. The movement of the piston rod 110 then forces the piston rod guide 130 to rotate with respect to the housing 160.
  • the dosing mechanism 100 is an exemplary dosing mechanism that has a first member that is configured to rotate with respect to a second member around the longitudinal axis 7 during dose setting and that is configured to transfer an axial force to the second member in the proximal direction 5 during dose delivery.
  • the first member thereby is formed by the driver 230 and the second member is formed by the nut 200.
  • the present disclosure relates, inter alia, at dosing mechanisms having such first and second members and in which a friction brake is provided in between the first member and the second member to provide a rotation brake between the first member and the second member when the first member transfers a force to the second member.
  • a friction brake is formed by a friction brake 225.
  • the friction brake 225 is exemplarily configured as a O-ring that sits on an outer surface 206 of the nut 200.
  • Fig. 33 depicts a cross-sectional side view in a cut plane parallel to the longitudinal axis 7 showing the nut 200 and the driver 230 with the friction brake 225 positioned in between and
  • Fig. 34 depicts a corresponding cross-sectional side view in a cut plane parallel to the longitudinal axis 7 and perpendicular to the cut plane of Fig. 33.
  • the nut 200 which is also shown in Figs. 35 to 39, comprises a generally cylindrical body 205 and a protruding part 220 that radially protrudes from the body 205.
  • the protruding part 220 is exemplarily located at a proximal end of the body 205.
  • the nut 200 comprises an inner thread 201 of the threaded connection 112 to the piston rod 110.
  • the protruding part 220 comprises the first latching part 223 of the latching mechanism 192 on its outer circumferential surface.
  • the first latching part 223 comprises a longitudinal protrusion located at a free end of a flexible arm.
  • the flexible arm extends in the circumferential direction and has a fixed end that is fixed to a bar 221 that radially extends from the body 205.
  • the first latching part 223 is configured to flex in the radial direction perpendicular to the longitudinal axis 7. It furthermore is configured to bend radially inward upon disengaging from the second latching part 193 of the inner housing 180.
  • the nut 200 comprises four of the first latching parts 223.
  • the first latching parts 223 are located pairwise opposite each other with respect to the longitudinal axis 7. Furthermore, each first latching part 223 is attached together with a neighboring first latching part 223 to a common bar 221 .
  • the nut 200 thereby comprises two of the bars 221 located at opposite positions with respect to the longitudinal axis 7.
  • the nut 200 comprises two rigid arms 224 each of which is connected by an additional one of the bars 221 to the body 205.
  • Outer circumferential surfaces of the flexible arms 222 and outer circumferential surfaces of the rigid arms 224 are configured as cylindrical surfaces around the longitudinal axis 7.
  • the circumferential surfaces of the flexible arms 222 and the circumferential surfaces of the rigid arms 225 thereby have the same radius.
  • the nut 200 In the distal direction from the protruding part 220, the nut 200 comprises a contact structure 210.
  • the contact structure 210 is spaced apart from the protruding part 220 in the distal direction. It thereby is separated from the protruding part 220 by a gap.
  • the contact structure 210 is configured as a radial protrusion extending from the outer surface 206 of the body 205. It forms a ring-like structure that circumferentially fully encloses the outer surface 206 of the body 205.
  • the contact structure 210 is located on a proximal side of the friction brake 225. It is configured to limit proximal movement of the friction brake 225.
  • the contact structure 210 comprises a contact section 211 that is configured to contact the friction brake 225. Furthermore, the contact section 211 is configured to stop movement of the friction brake 225 in the proximal direction 5.
  • the contact section 211 is configured as a contact surface.
  • the contact section 211 has a shape that is adapted to an outer shape of the proximal portion of the friction brake 225.
  • the shape is exemplarily formed as a rounded transition from the outer surface 206 of the body 205 to a radial surface portion of the first contact section 211 that is perpendicular to the longitudinal axis 7.
  • the contact section 211 circumferentially fully surrounds the longitudinal axis 7. Furthermore, the contact section 211 is configured to contact the friction brake 225 continuously around the longitudinal axis 7.
  • the driver 230 which is shown in detail in Figs. 40 to 42, radially surrounds the body 205 of the nut 200.
  • the driver 230 comprises a body 232 that is configured as a hollow cylindrical member.
  • An outer thread 231 of the threaded connection 255 to the dose member 250 is provided on an outer circumferential surface of the body 232.
  • the driver 230 comprises the radial protrusion of the end stop 235.
  • the driver 230 further comprises a protruding part 240 that radially protrudes from the body 230.
  • the protruding part 240 is located at a proximal end of the driver 230.
  • the protruding part 240 forms an axially protruding part that extends from the driver 230 parallel to the longitudinal axis 7.
  • the protruding part 240 comprises the at least one first lock element 241 of the rotation lock 202 between the driver 230 and the housing 160.
  • the first lock element 241 is configured as a radial tooth extending radially from the outer surface of the driver 240 and being elongated along the longitudinal axis 7.
  • the driver 230 comprises several of the first lock element 241 that are distributed around the circumference of the driver 230.
  • the protruding part 240 circumferentially surrounds the friction brake 225 and the contact section 21 1 of the nut 200 in the radial direction. It comprises an open end cavity 239 at the proximal end of the protruding part 240. The protruding part 240 thereby extends in the proximal direction 5 over the friction brake 225 and the contact section 21 1 towards the protruding part 220 of the nut 200.
  • the driver 230 comprises a contact section 242 that is located in the distal direction from the friction brake 225 along the longitudinal axis 7.
  • the contact section 21 1 of the nut 200, the friction brake 225 and the contact section 242 thereby are axially aligned with each other and axially overlap with each other parallel to the longitudinal axis 7.
  • the contact section 242 is circumferentially closed around the longitudinal axis 7. It forms a ring-like structure surrounding the longitudinal axis 7.
  • the contact section 242 is exemplarily formed as a contact surface. The contact surface is orientated perpendicular to the longitudinal axis 7.
  • the contact section 242 is located at a distal end of the end cavity 239. It forms an inwardly directed circumferential shoulder on an inner circumferential surface of the end cavity 239.
  • the contact section 242 is part of a contact structure 243 that is formed by the protruding part 240 of the driver 230.
  • the contact section 242 of the driver 230 forms a first contact section and the contact structure 243 of the driver 230 forms a first contact structure. Furthermore, the contact section 21 1 of the nut 200 forms a second contact section and the contact structure 210 of the nut 200 forms a second contact structure.
  • the first contact section 242 is configured to push against the friction brake 225 when the driver 230 is moved in the proximal direction 5 during dose delivery. This compresses the friction brake 225 between the first contact section 242 and the second contact section 21 1 .
  • a hard stop 218 is provided between the driver 230 and the nut 200.
  • the hard stop 218 comprises a first stop part 244 and a second stop part 219 that engage with each other when the friction brake 235 is compressed to a predefined maximum compression.
  • the first stop part 244 is provided at the driver 230, namely at the protruding part 240 of the driver 230
  • the second stop part 219 is provided at the nut 200, namely at the protruding part 220 of the nut 200.
  • the first stop part 144 is formed by a proximal end surface of the driver 230.
  • the end surface forms an end surface of an outer wall of the end cavity 239.
  • the end surface provides a first stop surface of the hard stop 218.
  • the second stop part 219 is formed by a distal facing surface of the nut 200.
  • the distal facing surface thereby forms a distal facing end surface of the protruding part 220.
  • the distal facing surface provides a second stop surface of the hard stop 218.
  • Figures 33 and 34 show the driver 230 and the nut 200 in a relaxed state when no axial force is applied to the driver 230. Furthermore, the driver 230 is positioned in its most distal position with respect to the nut 200. This most distal position is defined by a further stop 208 that acts between the nut 200 and the driver 240 and limits axial movement of the driver 230 in the distal direction with respect to the nut 200.
  • the further stop 208 comprises a first stop element 209 provided at the outer surface 206 of the nut 200 and a second stop element 237 provided on an inner surface of the driver 230. The first and second stop element 209, 237 engage with each other to limit the axial movement of the driver 230 in the distal direction with respect to the nut 200.
  • the first stop element 209 is configured as a radial protrusion on the outer surface 206 of the nut 200 and the second stop element 237 is configured as a radial protrusion on an inner surface of the driver 230.
  • the first stop element 209 has an angled distal surface that is configured to allow relative movement of the driver 230 in the proximal direction 5 with respect to the nut 200 during assembly of the dosing mechanism 100.
  • a proximal surface of the first stop element 209 is configured as a radial surface perpendicular to the longitudinal axis 7. It prevents detachment of the driver 230 from the nut 200 after assembly.
  • the first contact section 242 has an axial distance 603 from the friction brake 225. Furthermore, the first stop part 244 of the hard stop 218 has a distance 601 from the second stop part 219. The distance 601 thereby is larger than the distance 603. The difference between the distance 601 and the distance 603 defines the maximum compression of the friction brake 225.
  • the friction brake 225 is located within a cavity 226 that is radially bounded by the outer surface 206 of the nut 200 and an inner surface 246 of the end cavity 239 and that is axially bounded by the first and second contact sections 211 , 242.
  • a first radial spacing 615 between the nut 200 and the driver 230 at the distal end of the cavity 226 is smaller than the radial height 227 of the friction brake 225 from the nut 200 perpendicular to the longitudinal axis 7.
  • a second radial spacing 616 between the driver 230 and the nut 200 at the proximal end of the cavity 226 is smaller than the radial height 227 of the friction brake 225 from the nut 200.
  • the second contact section 211 overlaps with the friction brake 225 in the radial direction over a first radial height 611 . Furthermore, the first contact section 242 overlaps with the friction brake 225 over a second radial height 610.
  • the inner surface 246 of the driver 230 has a clearance 613 from the friction brake 225.
  • the clearance 613 may be large enough to prevent the friction brake 225 from touching the inner surface 246 when it has the predefined maximum compression.
  • the friction brake 225 has the clearance 613 from the driver 230 forming the outer member in a radial direction 803 that is orientated perpendicular to the longitudinal axis 7.
  • the radial direction 803 thereby extends from a center 801 of the friction brake 225 in the radial direction, which center 801 is located on the longitudinal axis 7 and located at the center of the friction brake 225 parallel to the longitudinal axis 7.
  • the friction brake 225 thereby exemplarily has the clearance 613 in all radial directions within a radial plane perpendicular to the longitudinal axis 7 and comprising the center 801 . As can be seen from Figs.
  • the nut 200 does not axially overlap with the friction brake 225 in between the friction brake 225 and the first contact section 242 of the driver 230 and the driver 230 does not axially overlap with the friction brake 225 in between the friction brake 225 and the second contact section 21 1 of the nut 200.
  • a plane through the center 801 of the friction brake 225 and orientated perpendicular to the longitudinal axis 7 defines a half space located at the side from the friction brake 225 that faces away from the first contact section 242 in the proximal direction 5 and a further half space located at the side from the friction brake 225 that faces away from the second contact section 21 1 in the distal direction opposite to the proximal direction 5.
  • the driver 230 forming the first member does not axially overlap with the friction brake 225 in the half space located at the side facing away from the first contact section 242 and the nut 200 forming the second member does not axially overlap with the friction brake 252 in the further half space located at the side facing away from the second contact section 21 1 .
  • the nut 200 forms a support member for the friction brake 225 and the friction brake is axially retained on the nut 200 by a friction fit. Furthermore, the driver 230 forms an outer member that at least partially surrounds the nut 200, which forms an inner member.
  • the second contact section 21 1 may also be provided at the protruding part 220 of the nut 200.
  • the second contact section 21 1 may be formed at the distal surface of the protruding part 220.
  • the friction brake 225 then may rest against the bars 221 .
  • the friction brake 225 is axially held in the proximal direction 5 at four separate locations around the circumference around the longitudinal axis 7.
  • the nut 200 may comprise an additional contact section that prevents the friction brake 225 from moving in the distal direction with respect to the nut 200.
  • the additional contact section may be formed by a depression on the outer surface 206 of the nut 200.
  • the additional contact section may comprise a radial protrusion that extends from the outer surface 206 and that overlaps with the friction brake 225 parallel to the longitudinal axis 7. The nut 200 then may axially overlap with the friction brake 225 in between the friction brake 225 and the first contact section 242 of the driver 230.
  • the friction brake 225 may also be configured as a disk-like washer that surrounds the nut 200.
  • the washer may be provided at one of the first and second contact section 21 1 , 242, for example at the second contact section 21 1 .
  • the friction brake 225 may also be integrally formed with one of the first and second contact section 21 1 , 242.
  • the friction brake 225 may be provided by one of the contact surfaces of the first and second contact sections 21 1 , 242.
  • the friction brake 225 then may be formed materially-uni- form with the respective one of the first and second contact sections 21 1 , 242.
  • the second contact section 211 may also be formed as a conical section of the outer surface 206 of the nut 200 and/or the first contact section 242 may also be formed as a conical section of the inner surface 246 of the driver 230, such as respective conical surfaces that are angled with respect to the radial plane perpendicular to the longitudinal axis 7.
  • Fig. 43 depicts a cross-sectional view of the driver 230, the nut 200, the inner housing 180, the dose member 250 and the piston rod 110 of the dosing mechanism 100 in a cut plane perpendicular to the longitudinal axis 7 through the protruding part 220 of the nut 200.
  • the outer circumferential surface of the protruding part 220 rests against the longitudinal webs 193.
  • the first latching parts 223 of the latching mechanism 192 engage with the longitudinal webs 193 and are positioned in between respective neighboring pairs of the longitudinal webs 193 to define a settable dose.
  • the rotation lock 273 between the nut 200 and the connector 270 comprises four longitudinal depressions 203 that engage with corresponding longitudinal ridges 274 on an inside surface of the connector 270, which is shown in Figs. 44 to 46.
  • the longitudinal depressions 203 generally form first longitudinal elements of the rotation lock 273 that engage with corresponding second longitudinal elements of the rotation lock 273, which are formed by the longitudinal ridges 274.
  • the four longitudinal depressions 203 shown in Fig. 39 are located pairwise opposite each other in the radial direction and are equally spaced from each other around the circumference of the nut 200.
  • Each depression 203 is configured to be fully accessible from one of two opposing radial directions, whereby the radial directions run horizontally in the view shown in Fig. 39.
  • Each radial depression 203 is configured to form an undercut of the nut 200 only in at least one of the radial directions. As a consequence, each radial depression 203 is fully opened in one of the radial directions.
  • the opposing depressions 203 are configured as rectangular depressions having radial side surfaces that run parallel to each other and parallel through a radial center axis 204, the radial center axis 204 cutting the central longitudinal axis 7 of the outer circumferential surface 206 of the nut 200.
  • the remaining two opposing depressions 203 face each other in a direction that is perpendicular to the radial center axis 204. They each form a step within the outer surface 206 that has a radial side surface 207 running perpendicular to the radial center axis 204 and a bottom surface that runs parallel to the radial center axis 204 and extends from the step to the outer surface 206.
  • the depressions 203 being fully accessible from one of the two opposing radial directions allows to fabricate the nut 200 in an injection molding process with a mold that has two halves that are detachable by moving them apart parallel to the radial center axis 204 and that rest against each other at the radial side surfaces 207.
  • connection part 272 forms a tubular portion having a through hole.
  • connection part 272 is surrounded by a tubular clutch part 271 that comprises first clutch parts 276 of the clutch 275 on its outer surface.
  • the first clutch parts 276 are configured as radially extending teeth.
  • the clutch part 271 is joined to the connection part 272 at the distal end of the clutch part 271 , where it forms the shoulder 278 that rests against the bearing 360.
  • the distal cylindrical part 277 extends distally from the shoulder 278 and has a reduced diameter compared to the clutch part 271 .
  • the axial lock 335 is formed on the inside surface of the distal cylindrical part 277.
  • the dosing mechanism 100 comprises a feedback mechanism 280 that provides an audible and/or tactile feedback to a user during dose delivery.
  • the feedback mechanism 280 comprises two flexible arms that protrude radially from the outer surface of the clutch part 271 .
  • the flexible arms are located opposite each other in the radial direction.
  • the flexible arms of the feedback mechanism 280 engage with radial teeth of the feedback mechanism 280 provided on an inside surface of the dose member 250, which is shown in Figs. 47 to 49.
  • the feedback mechanism 280 is active during dose delivery but not during dose setting since the connector 270 and the dose member 250 are rotationally fixed with each other during dose setting.
  • a connector 251 is located that axially and rotationally fixes the dose member 252 the dose setting element 310.
  • the connector 251 is configured as a snap-fit connector that allows to snap the dose setting element 310 onto the dose member 250 from the distal direction during assembly.
  • an inner thread of the threaded connection 255 between the driver 230 and the dose member 250 is provided on an inside surface of the inner sleeve of the dose member 250.
  • the inner sleeve is connected to an outer tubular portion of the dose member 250 by a shoulder.
  • the shoulder provides a bearing surface for the second biasing member 152.
  • the inner thread of the threaded connection 255 extends over the entire length of the inner tubular portion.
  • the dose member 250 comprises the markings 252 on its outer surface that are visible through the window 164 in the housing 162 and that indicate the set dose.
  • the markings 252 are arranged in a helical pattern on an outer surface of the dose member 250.
  • the dose member 250 forms a dose indication member of the dosing mechanism 100.
  • Figs. 50 to 52 depict the dose setting element 310.
  • the dose setting element 310 comprises the gripping structure 312 on its outer circumferential surface.
  • the gripping structure 312 is longitudinally structured to provide an enhanced grip to a user of the device.
  • the dose setting element 310 has a central through hole that receives the distal cylindrical part 277 of the connector 270. At its distal end, the dose setting element 310 forms an open cavity 311 that receives the bearing 360 and the button ring 340. At a bottom of the cavity 311 , the dose setting element 310 comprises a ring-like push surface 314 that rests against the bearing 360 when the button 330 is pushed in the proximal direction.
  • the push surface 314 is surrounded by openings of the connector 251 that axially and rotationally fix the dose setting element 310 to the dose member 250.
  • the push surface 314 is thereby located at an end of a rim that extends from the openings in the distal direction within the cavity 31 1 .
  • the dose setting element 310 further comprises a second clutch part 313 of the clutch 275.
  • the second clutch part 313 is configured as radially extending teeth on an inside surface of the dose setting element 310.
  • the second clutch part 313 is located at a proximal end of the dose setting element 310.
  • Figs. 53 and 54 depict the button ring 340 and Figs. 55 and 56 depict the button disc 332.
  • the button ring 340 has an inner radial wall and a proximal surface of the inner radial wall forms a push surface 343 that rests against the distal end surface of the bearing 360.
  • a central through hole 341 in the inner radial wall receives a tubular portion of the axial lock 335, which tubular portion is provided at a proximal side of the button disc 332.
  • the tubular portion has radially extending ridges on its outer circumferential surface which engage with corresponding radial protrusions on an inside surface of the distal cylindrical part 277 of the connector 270. The tubular portion of the button disc 332 is thereby received within the distal cylindrical part 277.
  • the axial lock 333 between the button disc 332 and the button ring 340 is formed by inwardly protruding radial protrusion at a distal end of the button ring 340 and corresponding radially protruding members provided at a proximal surface of the button disc 332.
  • the axial lock 333 is configured as a snap-fit connection that allows to snap the button disc 332 to distal end of the button ring 340.
  • a distal end surface of the button disc 332 forms a push surface 331 that is configured to be actuated by the user push the button 330 in the proximal direction 5.
  • Alternative embodiments of the medicament delivery device 1 may only comprise one, two or three of the cap alignment mechanism 80, the blocking mechanism 70, the friction brake 225 and the hard stop 218.
  • the medicament delivery device 1 is only one exemplary medicament delivery device that may feature the cap alignment mechanism 80, the blocking mechanism 70, the friction brake 225 and the hard stop 218.
  • the alignment mechanism 80 and/or the friction brake 225 and/or the hard stop 1 18 may also be provided with a medicament delivery device that is configured as a disposable device with a medicament holder non-releasably attached to a housing.
  • the friction brake 225 and/or the hard stop 1 18 may be provided with any medicament delivery device that has a first member that is configured to rotate with respect to a second member around a longitudinal axis during dose setting and that is configured to transfer an axial force to the second member in the proximal direction during dose delivery. Figs.
  • Figs. 60 to 62 depict a further embodiment of a medicament holder 740 according to the present disclosure that is configured to interact with the further embodiment of the cap end element 730.
  • the further embodiment of the cap end element 730 is configured as it is disclosed in connection with the cap end element 30 and vice versa.
  • the further embodiment of the medicament holder 740 is configured as it is disclosed in connection with the medicament holder 40 and vice versa.
  • the cap alignment mechanism comprises a first aligning part 760 of the medicament holder 740 and a second aligning part 735 of the cap end element 730.
  • first aligning part 760 is configured as it is disclosed for the first aligning part 60 of the medicament holder 40 and vice versa
  • second aligning part 735 is configured as it is disclosed for the second aligning part 35 of the cap end element 30 and vice versa.
  • the first aligning part 760 comprises the first sidewall 764 with the lead-in taper having the first taper angle 81 with respect to the longitudinal axis 7, see Fig. 62.
  • the second aligning part 735 is provided by a rounded end 738 of the second aligning part 735, whereby the rounded end 738 is located at a distal end of the second aligning part 735.
  • a rotation lock is provided between the medicament holder 740 and the cap 10 that rotation- ally locks the cap 10 comprising the cap end element 730 to the medicament holder 740 when the cap 10 is fully attached to the medicament holder 740.
  • the rotation lock is provided by engagement of the cap 10, exemplarily by engagement of the cap end element 730, with the medicament holder 740, whereby the cap 10, exemplarily the cap end element 730, engages the medicament holder 740 at its proximal end.
  • the rotation lock may be provided by other parts of the cap 10 engaging the medicament holder 740.
  • the rotation lock is formed by a locking member 742 of the medicament holder 740 and a locking member 732 of the cap 10, whereby the locking member 742 of the medicament holder 740 and the locking member 732 of the cap 10 are configured to engage with each other to prevent rotation of the cap 10 with respect to the medicament holder 740.
  • Both the locking member 742 of the medicament holder 740 and the locking member 732 of the cap 10 thereby extend in a length direction parallel to the longitudinal axis 7.
  • the locking member 742 is provided at an outer surface of the medicament holder 740 and the locking member 732 is provided at an inner surface of the cap 10. with the embodiment shown, the locking member 732 is provided at the cap end element 730.
  • the recess thereby is open at least at its proximal end. With the exemplary embodiment, the recess is open at both its proximal end and at its distal end.
  • the locking member 742 of the medicament holder 740 may also be formed as the protrusion and the locking member 732 of the cap 10 may be formed as the recess.
  • the locking member 742 of the medicament holder 740 is provided at a proximal end of the medicament holder 740 and the locking member 732 of the cap 10 is provided at a proximal end of the cap 10.
  • the rotation lock comprises at least one further sidewall 765, such as two opposing further sidewalls 765, of the medicament holder 740 engaging with at least one sidewall 737, such as with two sidewalls 737, of the cap 10.
  • each one of two further sidewalls 765 of the medicament holder 740 engages with a corresponding sidewall 737 of the cap 10.
  • the further sidewalls 765 thereby form sidewalls of the locking member 742 of the medicament holder 740.
  • the sidewalls 737 form sidewalls of the locking member 732 of the cap 10.
  • the sidewalls 737 are configured as sidewalls of the second aligning part 735.
  • the sidewalls 737 extend from the rounded end 738 of the second aligning part 735 in the proximal direction 5.
  • the sidewalls 737 are parallel to each other and parallel to a radial plane that runs through the longitudinal axis 7 and a longitudinal center line 731 of the second aligning part 735, see Fig. 58.
  • the further sidewalls 765 of the medicament holder 740 extend from the first sidewalls 764 forming the lead-in taper in the distal direction opposite the proximal direction 5.
  • the further sidewalls 765 are parallel to each other and parallel to the longitudinal axis 7. Furthermore, they are parallel to a radial plane that runs through the longitudinal axis 7 and a longitudinal center line in between the two further sidewalls 765.
  • the rotation lock is provided in between the cap 10 and the medicament holder 740 instead of the rotate-to-unlock mechanism provided between the cap end element 30 and the medicament holder 40 shown in Figs. 8 to 15.
  • Figs. 63 to 64 depict the piston rod 110 of the dosing mechanism 100 and Figs. 66 and 67 depict the piston bearing 120 of the dosing mechanism 100.
  • the piston rod 110 comprises a longitudinal flat 113 that runs parallel to the longitudinal axis 7 and that provides for the rotationally asymmetric radial cross-section of the piston rod 110 that rotationally locks the piston rod 110 to the piston rod guide 130.
  • a further longitudinal flat 113 is provided at an opposite side from the longitudinal flat 113.
  • the connector 122 that connects the piston bearing 120 to the piston rod 110 comprises a disc 117 provided at the proximal end of the piston rod 110, whereby the disc 117 is separated from a main body of the piston rod 110 by a circumferential recess 116. As can be seen from Figs.
  • the piston bearing 120 comprises a recess 126 provided at a lateral wall 125 delimiting the piston bearing 120 in the radial directions perpendicular to the longitudinal axis 7.
  • the recess 126 is configured to receive the disc 117 by moving the disc 117 perpendicular to the longitudinal axis 7 into the recess 126.
  • a central bore 123 connects from a top plate 121 into the recess 126.
  • the top plate 121 thereby delimits the piston bearing 120 in the distal direction.
  • the central bore 123 is connected with the lateral wall 125 by a notch 124 that runs parallel to the recess 126 within the top plate 121 and provides an opening in the top plate 121 into to the recess 126.
  • the recess 116 between the disc 117 and the main body of the piston rod 110 is received within the notch 124 upon mounting the piston bearing 120 to the piston rod 110.
  • the connector 122 comprises a snap-fit that restrains the piston bearing 120 on the piston rod 110 after attachment.
  • the snap-fit is provided by a narrowing 127 of the notch 124 at its transition to the central bore 123, whereby a width of the narrowing 127 is smaller than a diameter of the recess 116 connecting the disc 117 to the main body of the piston rod 110. Movement of the recess 116 of the piston rod through the narrowing 127 therefore requires elastic deformation of the narrowing 127.
  • the dosing mechanism (100) of embodiment 1 wherein the dosing mechanism (100) comprises a hard stop (218) that acts between the first member (230) and the second member (200) during dose delivery, wherein the hard stop (218) is configured to restrict a movement of the first contact section (242) towards the second contact section (211 ) during dose delivery and to limit the pressure applied to the friction brake (225).
  • the axial force is transferred from the first member (230) to the second member (200) via the hard stop (218) while the hard stop (218) is restricting the movement.
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the first contact section (242) circumferentially extends around the longitudinal axis (7), and/or wherein the second contact section (21 1 ) circumferentially extends around the longitudinal axis (7). 1 .
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the first contact section (242) is configured as a surface that is perpendicular to the longitudinal axis (7), and/or wherein the second contact section (21 1 ) is configured as a surface that is perpendicular to the longitudinal axis (7). 2.
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the first contact section (242) is configured as a first surface and the second contact section (21 1 ) is configured as a second surface, wherein the first surface is parallel to the second surface. 3.
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the first contact section (242) axially overlaps with the friction brake (225) over a first radial height (610) that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height (227) of the friction brake (225) and/or wherein the second contact section (211 ) axially overlaps with the friction brake (225) over a second radial height (611 ) that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height (227) of the friction brake (225).
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the dosing mechanism (100) comprises a further stop (208), wherein the further stop (208) acts between the first member (230) and the second member (200), wherein the further stop (208) restrains axial movement of the first contact section (242) away from the second contact section (211 ) during dose setting.
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the dosing mechanism (100) comprises a latching mechanism (192) that defines discrete rotational positions of the second member (200) with respect to the first member (230), wherein the first member (230) is permanently rotationally fixed to a first latching part (223) of the latching mechanism (192), wherein the second member (200) is permanently rotationally fixed to a second latching part (193) of the latching mechanism (192), wherein the first latching part (223) and the second latching part (193) releasably engage with each other upon relative rotation of the first member (230) relative to the second member (200), wherein the latching mechanism (192) provides an additional rotation brake preventing relative rotation of the first member (230) and the second member (200) during dose delivery.
  • the latching mechanism (192) provides an additional rotation brake preventing relative rotation of the first member (230) and the second member (200) during dose delivery.
  • the dosing mechanism (100) of at least embodiment 31 wherein the second latching part (193) is axially fixed to the second member (200), wherein the second contact section (211 ) and the second latching part (193) are separate from each other.
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the dosing mechanism (100) comprises a piston rod (110) that is configured to move into a medicament holder (40, 740) attachable to the dosing mechanism (100) to deliver the dose from the medicament holder (40, 740), wherein the piston rod (1 10) is rotationally fixed with respect to the first member (230) at least during dose delivery, wherein the second member (200) is coupled to the piston rod (1 10), for example engages the piston rod (1 10), via a threaded connection (1 12).
  • a medicament delivery device (1 ) having a medicament holder (40, 740), a housing (160), and a cap (10), wherein the medicament holder (40, 740) is configured to releasably attach to the housing (160) via a connector by rotating the medicament holder (40, 740) around a longitudinal axis (7) with respect to the housing (160), wherein the cap (10) is configured to releasably attach to the medicament holder (40, 740) to at least partly cover the medicament holder (40, 740).
  • the medicament holder (40, 740) comprises a first blocking element (50) of a blocking mechanism (70) that is configured to engage with a second blocking element (167) of the blocking mechanism (70), the second blocking element (167) being provided at the housing (160), wherein the blocking mechanism (70) is interlocked by the cap (10) to rotationally lock the medicament holder (40, 740) to the housing (160) when the cap (10) is attached to the medicament holder (40, 740), wherein the blocking mechanism (70) is unlocked to allow rotation of the medicament holder (40, 740) with respect to the housing (160) when the cap (10) is detached from the medicament holder (40, 740).
  • the connector (90) comprises a first connection element (41 ) provided at the medicament holder (40, 740), wherein the first connection element (41 ) is configured as a female connector that is configured to receive a second connection element (163) provided at the housing (160).
  • a cap lock (85) formed by the first cap lock element (47) and the second cap lock element (21 ) is configured as an axial lock that does not restrict rotation of the cap (10) with respect to the medicament holder (40, 740).
  • the medicament delivery device (1 ) of at least one of the preceding embodiments wherein the medicament holder (40, 740) comprises a first aligning part (60, 760) of a cap alignment mechanism (80) and the cap comprises a second aligning part (35, 735) of the cap alignment mechanism (80), wherein the first aligning part (60, 760) is configured to engage with the second aligning part (35, 735) upon attachment of the cap (10) to the medicament holder (40, 740) to attach the cap (10) in a predefined rotational orientation to the housing (160).
  • first aligning part (60, 760) and/or the second aligning part (35, 735) comprise a lead- in taper that narrows in a distal direction parallel to a longitudinal axis (7).
  • both the first aligning part (60, 760) and the second aligning part (35, 735) comprise the lead-in taper, wherein a first taper angle (81 ) of the first aligning part (60, 760) is larger than a second taper angle (82) of the second aligning part (35, 735).
  • the medicament delivery device (1 ) of at least one of embodiments 18 to 31 wherein the cap (10) comprises a cap body (20) and a cap end element (30, 730), wherein the cap end element (30, 730) is located at a proximal end of the cap body (20), wherein the second aligning part (35, 735) is formed at the cap end element (30, 730).
  • the medicament delivery device (1 ) of at least embodiment 41 wherein the recess is open at least at its proximal end, wherein, for example, the recess is open at both its proximal end and at its distal end.
  • the present disclosure is also directed at the following embodiments of a medicament delivery device: 1 .
  • the hard stop (218) defines a maximal compression of the friction brake (225), wherein, for example, the maximal compression is at most 0.2 mm, such as at most 0.15 mm, at most 0.1 mm, at most 0.9 mm, at most 0.8 mm or at most 0.7 mm.
  • the dosing mechanism (100) of at least one of the preceding embodiments wherein the first contact section (242) axially overlaps with the friction brake (225) over a first radial height (610) that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height (227) of the friction brake (225) and/or wherein the second contact section (211 ) axially overlaps with the friction brake (225) over a second radial height (611 ) that is at least 0.5 times, such as at least 0.6 times, at least 0.7 times or at least 0.8 times a radial height (227) of the friction brake (225).
  • the dosing mechanism (100) comprises a latching mechanism (192) that defines discrete rotational positions of the second member (230) with respect to the first member (200), the first member (230) is permanently rotationally fixed to a first latching part (223) of the latching mechanism (192), wherein the second member (200) is permanently rotationally fixed to a second latching part (193) of the latching mechanism (192), wherein the first latching part (223) and the second latching part (193) releasably engage with each other upon relative rotation of the first member (230) relative to the second member (200), wherein the latching mechanism (192) provides an additional rotation brake preventing relative rotation of the first member (230) and the second member (200) during dose delivery.
  • the latching mechanism (192) provides an additional rotation brake preventing relative rotation of the first member (230) and the second member (200) during dose delivery.
  • the present disclosure also relates to a medicament holder having the features of the medicament holder of the medicament delivery device of at least one of the preceding embodiments. Furthermore, the present disclosure relates to a housing having the features of the housing of the medicament delivery device of at least one of the preceding embodiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un mécanisme de dosage comprend un premier élément, un second élément et un frein à friction situé entre une première section de contact du premier élément et une seconde section de contact du second élément et le premier élément est conçu pour tourner par rapport au second élément pendant le réglage d'une dose. Le premier élément est configuré pour transférer une force axiale au second élément dans une direction proximale pendant l'administration de dose. La première section de contact est configurée pour presser le frein à friction vers la seconde section de contact pendant l'administration de dose de telle sorte que le frein à friction fournit un frein de rotation entre les premier et second éléments. Une butée dure agit entre le premier élément et le second élément pendant l'administration de dose, la butée dure étant conçue pour limiter un mouvement de la première section de contact vers la seconde section de contact pendant l'administration de dose.
PCT/EP2024/071438 2023-07-28 2024-07-29 Mécanisme de dosage Pending WO2025026968A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23188498.2 2023-07-28
EP23188498.2A EP4497457A1 (fr) 2023-07-28 2023-07-28 Mécanisme de dosage

Publications (1)

Publication Number Publication Date
WO2025026968A1 true WO2025026968A1 (fr) 2025-02-06

Family

ID=87519810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/071438 Pending WO2025026968A1 (fr) 2023-07-28 2024-07-29 Mécanisme de dosage

Country Status (2)

Country Link
EP (1) EP4497457A1 (fr)
WO (1) WO2025026968A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050609A1 (en) * 2000-03-24 2003-03-13 Bernard Sams One-way clutch mechanisms and injector devices
US20060258988A1 (en) 2003-11-03 2006-11-16 Joachim Keitel Injection device
US10213559B2 (en) * 2013-10-16 2019-02-26 Novo Nordisk A/S Drug delivery device with brake mechanism
US20200345945A1 (en) * 2017-01-23 2020-11-05 Sanofi Drive train for dial of a torsion-spring assisted wind-up injection device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050609A1 (en) * 2000-03-24 2003-03-13 Bernard Sams One-way clutch mechanisms and injector devices
US20060258988A1 (en) 2003-11-03 2006-11-16 Joachim Keitel Injection device
US10213559B2 (en) * 2013-10-16 2019-02-26 Novo Nordisk A/S Drug delivery device with brake mechanism
US20200345945A1 (en) * 2017-01-23 2020-11-05 Sanofi Drive train for dial of a torsion-spring assisted wind-up injection device

Also Published As

Publication number Publication date
EP4497457A1 (fr) 2025-01-29

Similar Documents

Publication Publication Date Title
US20250032719A1 (en) Drug Delivery Devices
US20250332349A1 (en) System for a Drug Delivery Device
US20230028688A1 (en) Electronic Module and Modular System for a Drug Delivery Device
WO2025026968A1 (fr) Mécanisme de dosage
JP2024517819A (ja) 注射デバイスのためのハウジング構成要素
EP4520367A1 (fr) Mécanisme d'administration de médicament
GB2632729A (en) Dose delivery mechanism
CN112423809A (zh) 用于药物输送装置的药筒单元
US20250269117A1 (en) Drive mechanism for an injection device
US20240207523A1 (en) Housing Components for an Injection Device
US20240207526A1 (en) Coded Housing Components for an Injection Device
RU2778067C1 (ru) Устройства доставки лекарственного средства
US20240226417A1 (en) Coded housing components for an injection device
US20240252760A1 (en) Coded housing components for an injection device
JP2024542087A (ja) 薬物送達デバイスおよび電子ユニット
JP2025508176A (ja) カートリッジアセンブリ及び固定部材
JP2025508174A (ja) カートリッジアセンブリ及び固定部材

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24745967

Country of ref document: EP

Kind code of ref document: A1